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ABSTRACT 
Background: Refractory cardiogenic shock (RCS), cardiac arrest (CA) and postarrest 
cardiogenic shock (CS) are associated with high mortality. Venoarterial extracorporeal 
membrane oxygenation (VA-ECMO) is increasingly used and can offer acute cardiopulmonary 
life support in this critically ill population but selection of VA-ECMO candidates remains 
challenging. There are limited data on which pre-VA-ECMO variables that predict outcome. 
Aims: To identify pre-VA-ECMO predictors for 90-day mortality in Study I unselected, Study 
II postcardiotomy and Study III non-surgical patients with RCS, and Study IV in patients 
with CA or postarrest cardiogenic shock prior to VA-ECMO were studied. 
Methods: Study I-IV were observational and retrospective. Study I included 181 mixed 
patients with RCS, Study II 105 patients with refractory postcardiotomy CS, Study III 76 non-
surgical patients with RCS and Study IV 72 patients with CA or postarrest CS prior to VA-
ECMO cannulation. The association between pre-implant variables and all-cause mortality at 
90 days was analyzed with uni- and multivariable logistic regression. 
Results: Study I. Main etiologies of RCS were post-cardiotomy failure 58%, acute myocardial 
infarction 22% and other medical etiologies 20%. Median duration of VA-ECMO support was 
7 days (interquartile range [IQR]: 3-13). The 90-day overall mortality was 54%. Arterial lactate 
(odds ratio [OR] per unit: 1.14; 95% confidence interval [CI]: 1.06-1.23; p <0.001), number of 
inotropes and vasopressors (OR per agent: 1.58; 95% CI: 1.13-2.21; p = 0.008), and ischemic 
heart disease (IHD), (OR: 2.90; 95% CI: 1.31-6.39; p = 0.008) were independent predictors of 
90-day mortality. Study II. Main surgical subgroups were single non-CABG 29%, isolated 
CABG 20%, 2 and 3 concomitant surgical procedures, 31% and 20%, respectively. Median 
duration of VA-ECMO was 7 days (IQR: 3-14). The 90-day overall mortality and in-hospital 
mortality was 57% and 56%, respectively. Arterial lactate (OR per unit: 1.22; 95% CI:1.07-
1.40; p = 0.004), and IHD (OR: 7.87; 95% CI: 2.55-24.3; p <0.001) were independent 
predictors of 90-day mortality. Study III. Main etiologies of RCS were acute myocardial 
infarction 51% and acute heart failure of other etiologies 49%. Median duration of VA-ECMO 
was 5 days (IQR: 2-11). The 90-day overall mortality was 49% and in-hospital mortality was 
50%. Arterial lactate (OR per mmol/L: 1.15; 95% CI: 1.06-1.24; p = 0.001) and number of 
inotropes and vasopressors (OR per agent: 2.14; 95% CI: 1.26-3.63; p = 0.005) were 
independent predictors of 90-day mortality. Study IV. Out-of-hospital CA occurred in 12% of 
the patients. Initial cardiac rhythm was non-shockable in 57%, and shockable in 43% of the 
patients. Median cardiopulmonary resuscitation duration was 21 minutes (IQR: 10-73, range:1-
197). No return of spontaneous circulation (ROSC) was present in 64% and postarrest CS in 
36% of the patients at VA-ECMO cannulation. Median duration of VA-ECMO was 5 days 
(IQR: 2-12). The 90-day overall mortality and in-hospital mortality were 57%, respectively, 
and 53% died during VA-ECMO. All survivors (43%) had cerebral performance category score 
1-2 at discharge to home. Initial non-shockable CA rhythm (OR: 12.2; 95% CI 2.83-52.7; p = 
0.001), arterial lactate (OR per unit: 1.15; 95% CI: 1.01-1.31; p = 0.041), and IHD (OR: 7.39; 
95% CI: 1.57-34.7; p = 0.011) as independent predictors of 90-day mortality. 
Conclusions: Identified independent pre-implant predictors for 90-day mortality after VA-
ECMO initiation were in Study I arterial lactate, number of inotropes and vasopressors, and 
IHD, Study II arterial lactate and IHD, Study III arterial lactate, number of inotropes and 
vasopressors, Study IV initial non-shockable CA rhythm, arterial lactate and IHD. These 
predictors are easily available for pre-VA-ECMO risk prediction. 
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1 INTRODUCTION AND BACKGROUND 
Cardiogenic shock occurs in 7-10% of patients with acute myocardial infarction (AMI),1 in 1% 
of patients following cardiac surgery2 and additionally affects patients with decompensated 
heart failure of other etiologies.3 The in-hospital mortality rate of cardiogenic shock varies 
between 40% and 90% depending on etiology, patient characteristics and therapeutic 
interventions.1, 3 Refractory cardiogenic shock, defined as cardiogenic shock unresponsive to 
conventional medical therapy, will unavoidably proceed to death.4 Refractory cardiogenic 
shock still has an overall in-hospital mortality rate of around 50%,3, 5 despite initiation of 
mechanical circulatory support systems.  
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is designed to temporarily 
(days to weeks) provide partial or complete (biventricular) cardiac or cardiopulmonary (in 
cases with concomitant pulmonary failure) support in patients with refractory cardiogenic 
shock, regardless of cause, aiming to bridge-to-decision, bridge-to-recovery i.e. the failing 
heart to functional recovery, or bridge-to-destination i.e. heart transplantation, long-term 
mechanical circulatory support, or other interventions including percutaneous coronary 
intervention (PCI) and cardiac surgery.6, 7  
The VA-ECMO circuit, implantation technique, and patient management during VA-ECMO 
is not the focus of this thesis and have been described in detail elsewhere.5, 6, 8-10 In short, the 
standard VA-ECMO procedure included whenever feasible cannulation of the femoral artery 
and vein or right internal jugular vein, typically using the Seldinger technique, by an open 
(surgical cut down) or percutaneous approach, along with an ipsilateral distal perfusion 
catheter to prevent limb ischemia.11 Central cannulation of the right atrium and ascending 
aorta is occasionally performed on patients who cannot be weaned from cardiopulmonary 
bypass (CPB) or because of lack of suitable peripheral vascular access. 
The VA-ECMO-circuit used in this thesis consisted of an external centrifugal pump 
(CardioHelp-i, Maquet, Rastatt, Germany or Thoratec CentriMag system, Pleasonton, CA, 
USA), a membrane oxygenator (Maquet HLS Module Advanced) and a tubing system 
(Maquet Bioline) with an integrated heat exchanger that ensure both circulation and 
oxygenation of tissues. The system has integrated pressure sensors, a venous probe to 
measure venous oxygen saturation, hemoglobin, hematocrit, venous temperature, and a flow-
bubble sensor. Deoxygenated blood is drained from the venous system and is pumped 
through a membrane oxygenator (artificial lung) before returning as oxygenated blood to the 
patient´s arterial circulation, in a similar fashion to standard CPB, which in contrast usually 
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includes a cardiotomy reservoir. By facilitating oxygen and carbon dioxide exchange, ECMO 
allows for reduction of ventilator settings (lung protective ventilation) or complete stop of 
ventilation to diminish the potential for lung injury.12 The major difference between the two 
main ECMO configurations, VA- and veno-venous (VV)-ECMO circuits (besides the veno-
pulmonary artery [VPa], veno-veno-arterial [VVA], veno-arterial-veno [VAV] and veno-
arterial-pulmonary artery [VAPa] modes) (Table 1) is the vascular insert location for the 
supply and drainage cannulas.13 The latter is only initiated in patients with isolated respiratory 
failure to provide pulmonary support while the lungs recover. This is achieved by draining 
deoxygenated blood from either the inferior vena cava by the femoral vein and returned to 
the right internal jugular vein, or vice versa (the latter not included in the original reference 
for Table 1), or by applying a bicaval dual-lumen catheter to provide both drainage and return 
directly into the right atrium via the internal jugular vein, without the need to insert a second 
venous cannula.  
TABLE 1. Cannulation modes for peripheral extracorporeal membrane oxygenation (ECMO) 
Drainage Return Strategy Draining  
cannula* 
Supplying  
cannula* 
Indication 
 
 V V  VV Inferior vena cava  
or superior vena 
cava†  
Superior vena cava 
or inferior vena 
cava† 
ARDS 
 V Pa  VPa Right atrium Pulmonary artery Rightsided cardiogenic shock 
 V A  VA Right atrium or 
superior vena cava† 
Common iliac artery Postcardiotomy cardiogenic shock 
Cardiogenic shock of other etiology 
Massive pulmonary embolism 
High risk PCI support 
Extracorporeal resuscitation 
V V A  VVA Inferior vena cava 
Superior vena cava  
Common iliac artery Insufficient unloading during VA-ECMO 
Left ventricular distension during  
VA-ECMO  
 V A V VAV Inferior vena cava Common iliac artery 
Superior vena cava 
Respiratory failure during VA-ECMO 
Cardiogenic shock during VV-ECMO 
 V A Pa VAPa Right atrium Common iliac artery 
Pulmonary artery 
Severe rightsided heart failure during  
VAV-ECMO 
Severe lung and rightsided heart failure 
during VA-ECMO 
© 2016 L. Napp and J. Bauersachs. Triple cannulation ECMO. Licensee InTechOpen. This image is distributed under the terms of the Creative 
Commons. Attribution License (http://creativecommons.org/licenses/by/3.0) 
 
A, arterial; ARDS, acute respiratory distress syndrome; Pa, pulmonary artery; PCI, percutaneous coronary intervention; V, 
venous. The nomenclature does not consider the arterial cannula for distal leg perfusion and does not change upon use of a 
bicaval dual-lumen cannula (VV-ECMO). *Typical place of blood supply/drainage (cannula tip), not place of vascular 
access/puncture. †Not included in the original table reference by L. Napp and J. Bauersachs. 
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VA-ECMO support has been reported to improve short and long-term survival in refractory 
cardiogenic shock in large registries, but with divergent success depending on etiology, 
patient characteristics and interventions.7, 14, 15 Furthermore, VA-ECMO is much less 
expensive than comparable mechanical circulatory support alternatives and can be rapidly 
deployed (within 15 minutes) by percutaneous insertion without access to the operating room.  
The concept of ECMO was first described in the 1970s.16, 17 Despite major advances in 
technology since it was first developed, VA-ECMO remains invasive, resource demanding, 
and associated with considerable risk for severe complications.6, 18-22 These include life-
threatening gas embolism, massive hemorrhage secondary to tubing ruptures or disconnections, 
blood clots in the circuit, loss of circuit flow (usually secondary to hypovolemia or suboptimal 
cannula placement), left ventricular distension as a consequence of the VA-ECMO initiated 
retrograde aortic flow, which causes a marked increase in the left ventricular afterload, 
impairing myocardial performance especially in severe contractile dysfunction,10, 23 differential 
hypoxia (“two circulation-syndrome”),24-27 thromboembolic events, infections, limb ischemia 
or secondary consequences of prolonged immobilization, and primary failure of circuit 
components. The potential life-saving benefits of VA-ECMO must therefore be weighed 
against its inherent risks and should therefore be restricted to selected patients in a medically 
appropriate and resource efficient manner.  
Data on prognosis and prognosing factors in patients treated with VA-ECMO are scarce and 
limited by small to moderate sample sizes and/or relatively short duration of follow-up.28-35 
Although evidence is lacking, VA-ECMO use in patients with refractory cardiogenic shock 
or cardiac arrest has risen considerably in recent years.36-38 Optimal selection of patients with 
refractory cardiogenic shock for VA-ECMO support is a field of increased interest due to 
promising outcomes in critically ill patients.14, 39-43 
The majority of studies have focused on postcardiotomy shock patients,2, 8, 34, 44-47 were VA-
ECMO is initiated in 0.6-2.9% of patients after routine cardiothoracic surgery.2, 34, 44, 46-50 The 
postcardiotomy cardiogenic shock VA-ECMO studies have focused on a combination of 
preoperative, surgical, and on-VA-ECMO (i.e. during support) variables to identify outcome 
predictors.8, 34, 44, 46, 47, 49-51 Despite VA-ECMO support, the in-hospital mortality rate in 
postcardiotomy cardiogenic shock is 53-84%50, 52-56 and is influenced by patient 
characteristics and surgical case mix.2, 34, 57 
Residual studies have evaluated non-surgical subgroups40, 58-62 or a combination of non-
surgical and surgical populations,14, 35, 39, 53, 63, 64 which makes the interpretation more difficult 
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as the two cohorts have different pathophysiological mechanisms. Limited data on 
independent pre-VA-ECMO outcome predictors in an unselected non-surgical population with 
refractory cardiogenic shock have been identified as previous studies have mainly included 
variables in the analysis from both before and after VA-ECMO was initiated.65, 66 Furthermore, 
previous studies have usually omitted to report rates of missing data or have presented results 
with considerably incomplete data14, 32, 33, 40, 61, 66 In addition, it is problematic to include 
variables after VA-ECMO initiation (i.e. during support) when the specific aim is to 
determine which patients who should be selected to receive this highly invasive therapy. 
Although refractory cardiogenic shock represents the majority of adult patients on VA-
ECMO,15 studies exclusively focusing on independent pre-VA-ECMO factors to facilitate 
pre-implant risk prediction of midterm outcomes in different refractory cardiogenic shock 
population have only scarcely been described.  
There are important medical, ethical and resource utilization aspects which motivate this 
thesis. VA-ECMO has the potential to save many lives but has heavy up-front costs and is 
associated with potentially severe complications. As this field expands it is important that 
selection criteria and ultimately guidelines are established. If VA-ECMO continues to be 
utilized based on vague and varying clinical indication, it is likely that payers will severely 
restrict its application and the potential to help many patients will be foregone.6  
Three main goals for VA-ECMO risk prediction can be considered. First, it should allow 
clinicians to prospectively stratify the outcome risk for VA-ECMO candidates. Second, it 
should also permit clinicians to retrospectively understand their risk-adjusted VA-ECMO 
performance across all their patients. Third, it should allow clinicians who wish to start an 
ECMO program to estimate future clinical performance from such a program.38 Hence, 
appropriate patient selection, timing for VA-ECMO initiation and identification of pre-VA-
ECMO predictors for survival are vital.64, 67 
The overall ambition of this thesis was to identify specifically pre-implant predictors for short 
and mid-term outcome in patients with cardiogenic shock of different etiologies supported 
with VA-ECMO. A further ambition was to present outcome data in predefined subgroups 
of patients, which may contribute to improve identification of suitable candidates before 
implant, increase our ability to predict outcome and handle patients during VA-ECMO. 
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2 AIMS 
The specific aims were: 
• To identify independent pre-VA-ECMO predictors for 90-day mortality in an 
undifferentiated refractory cardiogenic shock population supported by VA-ECMO. 
 
• To identify independent pre–VA-ECMO predictors for 90-day mortality in an 
unselected population with refractory postcardiotomy cardiogenic shock supported by 
VA-ECMO. 
 
• To identify independent pre-VA-ECMO predictors for 90-day mortality in an 
unselected non-surgical population with refractory cardiogenic shock. 
 
• To identify independent pre-VA-ECMO predictors for 90-day mortality in patients with 
cardiac arrest and CPR ≥1 minute prior to VA-ECMO, independently if VA-ECMO 
was initiated during CPR or if ROSC was achieved but postarrest cardiogenic shock 
ensued. 
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3 METHODS 
3.1 STUDY DESIGN AND PATIENT SELECTION 
 
Study I-IV were observational, retrospective, single tertiary center studies where we in Study 
I started by reviewing the medical records of 181 consecutive patients, who received VA-
ECMO support for refractory cardiogenic shock between September 2006 and April 2015 at 
the Department of Cardiothoracic Surgery and Anesthesiology at the Karolinska University 
Hospital in Stockholm, Sweden. VA-ECMO was initiated due to refractory cardiogenic shock 
as a rescue therapy when other therapeutic options were exhausted. 
 
In Study II we restricted the inclusion criteria to patients who received VA-ECMO support 
for refractory postcardiotomy cardiogenic shock during the same study period resulting in 
105 consecutive patients. The patients were included in the study irrespective of locality or 
timing of VA-ECMO initiation, i.e. intraoperatively or postoperatively in the ICU.   
 
The 76 consecutive patients with refractory cardiogenic shock included in Study III had not 
undergone surgery prior to VA-ECMO implantation. 
 
The selection criteria for Study IV were 72 patients presenting with in- or out-of-hospital 
cardiac arrest, presumed or confirmed to be of cardiac etiology by presenting symptom, 
coronary angiography, echocardiography, and computed tomography where applicable, 
receiving conventional CPR duration (low-flow duration) of  ≥1 minute and where CPR 
either continued until VA-ECMO had been employed or resulted in sustained return or 
spontaneous circulation (ROSC) followed by refractory postarrest cardiogenic shock before 
VA-ECMO. All cardiac arrests were witnessed by trained medical personnel who 
immediately initiated conventional CPR (emergency medical team present at start of out-of-
hospital cardiac arrest), which limited the no-flow time to almost zero and excluded by-
stander impact on CPR quality. Patients with out-of-hospital cardiac arrest were transported 
to our institution for immediate evaluation for suitability as candidates for VA-ECMO 
support (all cannulations were performed in-hospital). 
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3.2 CLINICAL INTERVENTIONS AND PROCEDURES 
At present, there are no universal criteria for initiation of VA-ECMO support for refractory 
cardiogenic shock. Our unit considers VA-ECMO as salvage therapy for evidence of persistent 
hypoperfusion and tissue hypoxia, secondary to severe and refractory cardiac or 
cardiopulmonary failure, despite adequate intravascular volume loading and support with high 
doses of inotropes and vasopressors.  
Patients were candidates for VA-ECMO support when there was a potential for recovery, heart 
transplantation or as a bridge to long-term mechanical assist device (LVAD). Exclusion criteria 
included cerebral hemorrhage, severe aortic valve insufficiency, aortic dissection, short-life 
expectancy due to other medical conditions, advanced age, or non-witnessed cardiac arrest. All 
patients were considered to have negligible chance of survival without initiating VA-ECMO 
support. The final decision for initiation of VA-ECMO was made by the cardiothoracic 
surgeon, the cardiothoracic intensivist, and the ECMO specialist. The device, implantation 
technique and patient management has been described elsewhere.5, 6, 8, 9, 42 In brief, the 
standard VA-ECMO procedure included whenever feasible cannulation of the femoral artery 
and vein either by surgical cut down or percutaneous puncture, along with a distal perfusion 
catheter to prevent limb ischemia (Figure 1).  
 
Central cannulation of the right atrium and ascending aorta was occasionally performed on 
patients who could not be weaned from cardio-pulmonary bypass (CPB) or because of lack 
of suitable peripheral vascular access. The VA-circuit consisted of a centrifugal pump 
(CardioHelp-i, Maquet, Rastatt, Germany or Thoratec CentriMag system, Pleasonton, CA, 
USA), a membrane oxygenator (Maquet HLS Module Advanced) and a tubing system 
(Maquet Bioline) with an integrated heat exchanger. Suitable refractory cardiogenic shock 
patients at external hospitals were placed on VA-ECMO and transported to our institution by 
our mobile ECMO unit.  
 
In general, when cardiac and pulmonary recovery was considered to be adequate weaning 
from VA-ECMO was attempted. If weaning failed and no further cardiac recovery was 
expected, bridging to LVAD or transplantation was considered as an alternative in patients 
with a suspected favorable neurological prognosis. Patients with severe neurological injuries 
were weaned off VA-ECMO during withdrawal of life support. 
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© 2016 L. Napp and J. Bauersachs. Triple cannulation ECMO. Licensee InTechOpen. This image is distributed under the terms of the 
Creative Commons. Attribution License (http://creativecommons.org/licenses/by/3.0) 
 
FIGURE 1. Venoarterial (VA)-ECMO via the femoral vessels drains venous blood (blue) from the right atrium 
and returns an equal volume after reoxygenation and decarboxylation (red) to the iliac artery towards the aorta. 
Femoral artery cannulation requires an extra shunt cannula for antegrade perfusion of the leg (inset).  
 
Regarding weaning from CPB in surgical patients, no registration of the number of weaning 
attempts was documented to allow complete inclusion and evaluation. But more importantly, 
there is no general protocol for the individual weaning procedure from CPB. The weaning 
procedure is individualized primarily depending on the individual patient’s cardiovascular 
response to the lowering of the CPB flow rate but also on the preferences of the individual 
surgeon and intensivist. In uncomplicated cases where patients display a sufficient cardiac 
reserve the weaning procedure can be performed more rapidly during simultaneous 
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assessment of cardiac function (including evaluation of the preceding surgical procedure 
performed e.g. valve repair, coronary graft flow etc.). In other cases, remaining valve issues 
or insufficient coronary anastomotic flow etc. may become overt during low CPB weaning 
flow rates with need for additional valve or coronary anastomotic re-interventions whereby 
the weaning procedure is aborted and full CPB is reinstituted. If the surgical reintervention 
is successful these patients may be weaned at the second attempt but will in case with focus 
on numbers of weaning attempts be registered as having undergone two weaning attempts 
which could be interpreted as more “worse” than patients that fail the first weaning attempt 
due to surgically non-restorable refractory postcardiotomy shock and not a more “benign” 
and correctable surgical cause. The pre-VA-ECMO cardiovascular state in patients with 
refractory postcardiotomy shock can be considered to contain more robust data when to 
identify pre-VA-ECMO outcome predictors compared with the more subjectively decided 
number of weaning attempts or other pre-VA-ECMO interventions. 
 
3.3 DATA COLLECTION 
Patient’s characteristics, complications and outcome data were acquired from medical records, 
including clinical presentation, interventions and the latest available laboratory data before VA-
ECMO onset, and were retrospectively analyzed. Patients were in Study I-IV divided between 
survivors and non-survivors at 90 days after VA-ECMO-initiation. Additionally, in each study 
patients were further subdivided in mutually exclusive groups; Study I: AMI, postcardiotomy 
and other medical etiologies; Study II: single non-coronary artery bypass grafting (non-
CABG), isolated CABG, and 2 and 3 concomitant surgical procedures according to the 
euroSCORE II classification (European System for Cardiac Operative Risk Evaluation) of 
cardiac surgical procedures; Study III: AMI and acute heart failure (AHF) of other etiologies, 
and Study IV: Absence of ROSC and postarrest cardiogenic shock i.e. ROSC. 
 
3.4 ETHICS 
The thesis is based on four retrospective studies, all patients had already received VA-ECMO 
support as they were considered to have negligible chance of survival without initiating VA-
ECMO support. Therefore, no randomization was performed between receiving VA-ECMO 
support or to proceed with pharmacological, volume loading or support with other mechanical 
support systems (i.e. intra-aortic balloon pump [IABP], Impella®, TandemHeart™). Such a 
 11 
 
randomization would have raised serious ethical concerns in this population being under acute 
life-threatening conditions.    
This thesis will contribute to a better identification of suitable candidates before implant and 
increase our ability in prognosing and treating patients on VA-ECMO. 
The studies of this thesis conform to the principles of the Helsinki Declaration and ethics 
approval has been obtained from the Regional Ethical Review Board in Stockholm (Project 
No. 2008/1695-31, 2012/119-32). No individual patient or family consent was obtained. No 
experimental interventions were performed.  
 
3.5 DEFINITIONS 
 
The definitions used throughout the thesis conform to those presented in Study I-IV to avoid 
any misinterpretation. Refractory cardiogenic shock was defined as cardiogenic shock with 
evidence of progressive tissue hypoxia and end organ failure unresponsive to conventional 
medical therapy including inotropes and adequate fluid management. Ischemic heart disease 
(IHD) was defined as a history of myocardial infarction, angina pectoris, percutaneous 
coronary intervention/CABG, or when prior coronary angiography had shown evidence of 
coronary artery disease according to multidisciplinary conferences. Chronic renal failure was 
defined as the estimated preoperative glomerular filtration rate of less than 60 mL/min/1.73 
m2 present for more than 3 months (in accordance with the US National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative guidelines 2012).68 Number of inotropes and 
vasopressors was defined as the total number of intravenous inotropes and vasopressors 
(epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, 
levosimendan), pre-VA-ECMO data as the latest clinical and laboratory data just before VA-
ECMO cannulation, and data defined “prior” refers to data previous to the current medical 
event/admission. Chronic cardiomyopathy was defined as symptomatic, non-ischemic or 
ischemic cardiomyopathy for more than 6 months since diagnose or if a second 
hospitalization due to heart failure decompensation occurred within 6 months from diagnosis. 
Multiorgan failure was defined as physiological derangement in 2 or more organ systems.  
 
CPR included all cardiopulmonary resuscitation episodes from the time of the current 
hospital admission: preoperative (before CPB) and postoperative until initiation of VA-
ECMO (Study II). CPR included all CPR episodes within 12 hours before VA-ECMO onset 
 12 
(Study I, III-IV). No-flow duration was defined as the time (without chest compressions) 
from cardiac arrest to initiation of CPR, and low-flow duration as the time with CPR (i.e. 
CPR duration) until sustained ROSC was achieved or VA-ECMO initiated. ROSC was 
defined as the restoration of a spontaneous perfusing rhythm (evidence of restored 
circulation) that resulted in breathing (more than an occasional gasp), palpable pulse, 
measurable blood pressure or an arterial waveform (approximately >30 seconds), with no 
chest compressions given. Postarrest cardiogenic shock following sustained ROSC was 
defined as myocardial dysfunction with progressive hypoperfusion and tissue hypoxia 
refractory to intravascular volume loading and increasing doses of inotropic and vasopressor 
agents.  
 
3.6 OUTCOME DEFINITIONS  
3.6.1 Primary outcome 
The primary outcome was defined as death from any cause at 90 days after VA-ECMO cannula 
insertion (Study I-IV).  
3.6.2 Secondary outcomes 
Successful weaning was defined as survival more than 48 hours after weaning from VA-ECMO 
or without need of re-initiation of VA-ECMO. Favorable neurological outcome was defined 
as cerebral performance category scores69 of 1 (good performance) and 2 (moderate 
disability) on a 5-point scale (Table 2) at the time of hospital discharge to home (Study II-
IV).  
TABLE 2. Cerebral performance category score 
CPC score Cerebral Performance 
CPC 1 Good cerebral performance: conscious, alert, able to work, might have mild neurological or 
psychological deficit 
CPC 2 Moderate cerebral disability: conscious, sufficient cerebral function for independent activities 
of daily life. Able to work in sheltered environment 
CPC 3 Severe cerebral disability: conscious, dependent on others for daily support because of 
impaired brain function. Ranges from ambulatory state to severe dementia or paralysis. 
CPC 4  Coma or vegetative state: any degree of coma without the presence of all brain death criteria. 
Unawareness, even if appears awake (vegetative state) without interaction with environment; 
may have spontaneous eye opening and sleep/awake cycles. Cerebral unresponsiveness.  
CPC 5  Brain death: apnea, areflexia, EEG silence, etc. 
CPC, cerebral performance score; EEG, electroencephalogram 
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3.7 STATISTICS 
 
The statistical methods used in the Study I-IV were coherent as the overall aim of the thesis 
was to identify preimplant outcome predictors. No patients were lost to follow up in Study 
I-IV.  
 
Initial analysis compared pre-VA-ECMO variables between survivors and non-survivors at 
90 days after initiation of VA-ECMO support. Categorical variables were presented as 
numbers and percentages, and compared with the Chi-square, Likelihood ratio or Fisher’s 
exact tests. Whereas most continuous baseline variables were non-normally distributed, a 
conservative approach was taken with all data expressed as median and interquartile range 
(IQR) and compared with the Mann-Whitney U test. A univariable logistic analysis was used 
to determine the pre-VA-ECMO-implant variables for death at 90-days after VA-ECMO 
initiation. Statistical significance was set to p <0.05. Prior to multivariable logistic regression 
analysis, variables identified as being significant in the univariable analysis were subjected 
to multicollinearity analysis by using the Spearman rho correlation coefficient.  
 
To assess the impact of non-linearity on the logistic regression analysis (Study II-IV) the 
continuous variables included in the model were tested by using restricted cubic splines with 
both 3 and 4 knots (default placements). Inclusion of restricted cubic splines in the statistical 
analysis provides a method to formally test the assumption of a linear relationship between a 
predictor and the outcome using standard methods i.e. testing the hypothesis that the 
relationship is not linear or summarizing a relationship that is too non-linear to be usefully 
summarized by a linear relationship. Failure to identify nonlinearity and include it in a model 
can result in an overestimated or underestimated relationship, or a relationship that is missed 
altogether. When non-linear relationships exist, splines allow it to be modelled well, reducing 
model misspecification and providing insight into the relationship between predictor and 
outcome (Croxford. R. Restricted Cubic Spline Regression: A Brief Introduction. Paper 
5621-2016. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada, 
http://support.sas.com/resources/papers/proceedings16/5621-2016.pdf). The acquired 
Akaike information criterion (AIC) and Bayesian information criterion (BIC) values were 
then compared with the corresponding AIC and BIC values of the original models.  
 
Goodness of fit was verified by the Hosmer-Lemeshow´s test indicating that the number of 
deaths was not significantly different from those predicted by the models and that the overall 
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fit of the models was good. A cumulative survival curve for 90 days follow-up was generated 
utilizing the Kaplan-Meier method and compared using the log rank test. Statistical analyses 
were performed with SPSS version 23 and 25 for Windows (IBM SPSS Statistics, NY, US) 
and Stata Statistical Software: Release 14 (StataCorp LP, College Station, TX, US). 
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4 RESULTS 
No patients were lost to follow up and there were no VA-ECMO device-related deaths in 
Study I-IV. 
4.1 STUDY I 
Pre-VA-ECMO variables and comparison between survivors and non-survivors within 90 
days after initiation of VA-ECMO support are summarized in Table 3. Median age was 58 
years (interquartile range [IQR]: 47-66), which was significantly lower in survivors (55 years; 
IQR: 40-64) compared with non-survivors (61 years; IQR: 50-67; p = 0.007). Overall, the most 
common (mutually exclusive) indication for VA-ECMO support was postcardiotomy (n = 
105; 58%), followed by AMI (n = 39; 22%) and other medical etiologies (n = 37; 20%). IHD 
was present in 56% (n = 102) of the study population, and the corresponding values for 
multiorgan failure, arterial lactate, number of inotropes and vasopressors, and previous CPR 
was 70% (n = 126), 7.1 mmol/L (IQR: 3.1-14.0), 2 (IQR: 2-3), and 40% (n = 72), respectively. 
VA-ECMO was implanted under cardiac compressions in 25% of the patients (n = 46).  
TABLE 3. Comparison of pre–VA-ECMO characteristics between survivors and nonsurvivors at 90 days after 
VA-ECMO initiation 
Pre-VA-ECMO 
characteristics  
MD 
(%) 
All patients 
(n = 181) 
Survivors  
(n = 84) 
Non-survivors 
(n = 97) 
P value 
Gender      
Female  0 45 (25) 23 (51) 22 (49) - 
Male  0 136 (75) 61 (45) 75 (55) 0.466 
Age (y)  0 58 (47-66; 11-77) 55 (40-64; 16-76) 61 (50-67; 11-77) 0.007 
<65 (y) 0 130 (72) 67 (52) 63 (48) - 
≥65 (y) 0 51 (28) 17 (33) 34 (67) 0.027 
Weight (kg) 0 79 (70-92; 39-143) 80 (68-92; 45-143) 78 (71-93; 39-130) 0.766 
BMI (kg/m2) 0 25.8 (23.4-29.3) 25.6 (23.1-29.0) 25.9 (23.5-29.4) 0.623 
Etiology of RCS      
AMI  0 39 (22) 19 (49) 20 (51) 0.744 
Postcardiotomy 0 105 (58) 45 (43) 60 (57) 0.260 
Other medical* 0 37 (20) 20 (54) 17 (46) 0.296 
Ischemic heart 
disease 
0 102 (56) 35 (34) 67 (66) <0.001 
Smoking 0 82 (45) 33 (40) 49 (60) 0.130 
Hypertension 0 73 (40) 30 (41) 43 (59) 0.239 
Chronic renal failure 0 17 (9.4) 6 (35) 11 (65) 0.334 
Diabetes mellitus 0 28 (16) 9 (32) 19 (68) 0.100 
Dyslipidemia  0 53 (29) 19 (36) 34 (64) 0.067 
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Atrial fibrillation 0 33 (18) 12 (36) 21 (64) 0.201 
Valvular heart 
disease  
0 92 (51) 45 (49) 47 (51) 0.492 
Prior†AMI  0 27 (15) 10 (37) 17 (63) 0.290 
Prior† PCI 0 16 (8.8) 5 (31) 11 (69) 0.203 
Prior† cardiac surgery 0 37 (20) 13 (35) 24 (65) 0.123 
Multiorgan failure  0 126 (70) 51 (41) 75 (59) 0.015 
LVEF (%)‡   0 15 (0-39) 20 (11-50) 13 (0-25) <0.001 
≥20 (%) 0 79 (44) 47 (60) 32 (40) - 
<20 (%) 0 102 (56) 37 (36) 65 (64) 0.002 
MAP (mm Hg)‡ 0 54 (44-65) 60 (50-68) 50 (40-60) <0.001 
≥50 (mm Hg)  0 118 (65) 66 (56) 52 (44) - 
<50 (mm Hg) 0 63 (35) 18 (29) 45 (71) <0.001 
Arterial pH‡ 0 7.24 (7.10-7.32; 
6.55-7.57) 
7.29 (7.17-7.36; 
6.63-7.57) 
7.20 (7.04-7.30; 
6.55-7.49) 
<0.001 
≥7.00  0 158 (87) 79 (50) 79 (50) - 
<7.00 0 23 (13) 5 (22) 18 (78) 0.011 
Arterial lactate 
(mmol/L)‡ 
0 7.1 (3.1-14.0;  
0.4-28.0) 
4.0 (2.1-9.3;  
0.4-20.0) 
10.2 (5.2-16.0;  
0.7-28.0) 
<0.001 
<5 (mmol/L) 0 69 (38) 47 (68) 22 (32) - 
5-9,9 (mmol/L) 0 47 (26) 22 (47) 25 (53) - 
10-14,9 (mmol/L) 0 29 (16) 9 (31) 20 (69) - 
15-19,9 (mmol/L) 0 24 (13) 5 (21) 19 (79) - 
≥20 (mmol/L) 0 12 (6.6) 1 (8) 11 (92) 0.004 
<20 (mmol/L) 0 169 (93) 83 (49) 86 (51) - 
≥20 (mmol/L) 0 12 (6.6) 1 (8) 11 (92) 0.006 
Hemoglobin (g/L)‡ 0 100 (89-119) 101 (89-122) 100 (89-117) 0.454 
CRP (mg/L) 10 54 (12-158) 53 (10-156) 59 (13-166) 0.553 
WBC (109/L) 9.4 11.7 (8.0-16.5) 12.4 (8.0-17.3) 11.1 (7.9-15.7) 0.380 
Platelets (109/L) 6.1 168 (102-234) 173 (106-226) 166 (100-238) 0.978 
INR 7.7 1.3 (1.1-1.6) 1.3 (1.1-1.6) 1.4 (1.2-1.7) 0.041 
Creatinine (µmol/L)  1.7 121 (92-166) 116 (80-154) 125 (94-183) 0.126 
GFR MDRD 
(mL/min/1.73m2) 
1.7 53 (39-77) 55 (43-87) 52 (34-72) 0.070 
ALT (µkat/L) 7.7 1.29 (0.54-4.90) 0.97 (0.48-4.86) 1.43 (0.59-5.26) 0.296 
Pre-VA-ECMO 
interventions 
     
Acute PCI 0 43 (24) 19 (44) 24 (56) 0.738 
CPR  0 72 (40) 31 (43) 41 (57) 0.462 
Hemodialysis 0 31 (17) 14 (45) 17 (55) 0.878 
No. of inotropes and 
vasospressors‡§ 
0 2 (2-3) 2 (2-3) 3 (2-4) 0.001 
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1 0 31 (17) 20 (65) 11 (35) - 
2 0 64 (35) 33 (52) 31 (48) - 
3 0 47 (26) 20 (43) 27 (57) - 
≥4 0 39 (22) 11 (28) 28 (72) 0.017 
IABP 0 15 (8.3) 6 (40) 9 (60) 0.603 
Retrieved from 
external hospital  
0 64 (35) 29 (45) 35 (55) 0.827 
VA-ECMO insertion 
period¶  
     
2006-2010  0 93 (51) 38 (41) 55 (59) - 
2011-2015  0 88 (49) 46 (52) 42 (48) 0.124 
Bold indicates statistical significance. Categoric variables are presented as n (%) and compared with the chi-square, likelihood 
ratio, or Fisher exact test. Continuous variables are presented as median (IQR; range) and compared with the Mann–Whitney 
U test. ALT, alanine aminotransferase; AMI, acute myocardial infarction; BMI, body mass index; CPR, cardiopulmonary 
resuscitation; GFR MDRD, glomerular filtration rate modification of diet in renal disease; IABP, intra-aortic balloon pump; 
INR, international normalized ratio; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; MD, missing data; 
PCI, percutaneous coronary intervention; RCS, refractory cardiogenic shock; VA-ECMO, venoarterial extracorporeal 
membrane oxygenation; WBC, white blood cell counts. *Acute decompensated heart failure (n = 29), intoxication (n = 3), 
acute pulmonary embolus (n = 3), drowning (n = 1), endocarditis (n = 1). †Prior to current medical event/admission. ‡Just 
before cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan. 
¶Postimplant variable only for descriptive purposes. 
Numerous variables were found significantly associated with 90-day mortality in univariable 
analysis: age, IHD, multiorgan failure, left ventricular ejection fraction (LVEF), mean arterial 
pressure (MAP), arterial pH, arterial lactate, INR and number of inotropes and vasopressors 
(Table 4A). 
TABLE 4A. Factors associated with mortality within 90 days after VA-ECMO initiation 
 Univariable logistic regression  Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
Male gender  0 1.29 0.65-2.53 0.466 - - - 
Age (y)  0 1.03 1.01-1.05 0.007 1.03 0.99-1.05 0.055 
≥65 vs. <65 (y) 0 2.13 1.08-4.18 0.029 - - - 
Weight (kg) 0 1.01 0.99-1.02 0.598 - - - 
BMI (kg/m2) 0 1.02 0.93-1.11 0.736 - - - 
Etiology of refractory CS        
AMI 0 1.13 0.55-2.29 0.744 - - - 
Postcardiotomy 0 1.12 0.92-1.37 0.261 - - - 
Other medical* 0 0.83 0.57-1.19 0.297 - - - 
Ischemic heart disease 0 3.13 1.70-5.80 <0.001 2.90 1.31-6.39 0.008 
Smoking 0 1.58 0.87-2.85 0.131 - - - 
Hypertension 0 1.43 0.79-2.61 0.239 - - - 
Chronic renal failure 0 1.66 0.59-4.71 0.338 - - - 
Diabetes mellitus 0 2.03 0.86-4.77 0.104 - - - 
Dyslipidemia 0 1.85 0.96-3.57 0.069 - - - 
Atrial fibrillation 0 1.66 0.76-3.61 0.203 - - - 
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Valvular heart disease  0 0.67 0.37-1.20 0.177 - - - 
Prior† myocardial 
infarction 
0 1.57 0.68-3.65 0.292 - - - 
Prior† PCI 0 2.02 0.67-6.07 0.210 - - - 
Prior† cardiac surgery 0 1.80 0.85-3.80 0.126 - - - 
Multiorgan failure  0 2.21 1.16-4.21 0.016 1.10 0.48-2.50 0.828 
LVEF (%)‡ 0 0.97 0.96-0.99 0.001 0.99 0.97-1.01 0.248 
<20 vs. ≥20 (%) 0 2.58 1.41-4.72 0.002 - - - 
MAP (mmHg)‡ 0 0.96 0.94-0.99 <0.001 0.99 0.96-1.01 0.387 
<50 vs. ≥50 (mmHg) 0 3.17 1.65-6.12 0.001 - - - 
Arterial pH‡ 0 0.04 0.01-0.24 <0.001 - - - 
<7.00 vs.  ≥7.00 0 3.60 1.27-10.2 0.016 - - - 
Arterial lactate (mmol/L)‡ 0 1.15 1.09-1.21 <0.001 1.14 1.06-1.23 <0.001 
<5 (mmol/L) 0 Ref. - - - - - 
5-9.9 (mmol/L) 0 2.43 1.13-5.22 0.023 - - - 
10-14.9 (mmol/L) 0 4.75 1.86-12.1 0.001 - - - 
15-19.9 (mmol/L) 0 8.12 2.68-24.6 <0.001 - - - 
≥20 (mmol/L) 0 23.5 2.85-193.6 0.003 - - - 
Hemoglobin (g/L)‡ 0 1.00 0.98-1.01 0.483 - - - 
CRP (mg/L) 10 1.00 0.99-1.00 0.320 - - - 
WBC (109/L) 9.4 0.98 0.94-1.01 0.179 - - - 
Platelets (109/L) 6.1 1.00 0.99-1.00 0.635 - - - 
INR 7.7 1.37 0.91-2.06 0.131 - - - 
Creatinine (µmol/L)  1.7 1.00 0.99-1.01 0.454 - - - 
GFR MDRD 
(mL/min/1.73m2) 
1.7 0.99 0.98-1.00 0.144 - - - 
ALT (µkat/L) 7.7 1.00 0.98-1.03 0.809 - - - 
Pre-VA-ECMO 
interventions 
       
Acute PCI 0 1.13 0.57-2.24 0.738 - - - 
CPR  0 1.25 0.69-2.28 0.462 - - - 
Hemodialysis  0 1.06 0.49-2.31 0.878 - - - 
Intra-aortic balloon 
pump 
0 1.33 0.45-3.90 0.604 - - - 
No. of inotropes and 
vasopressors‡§ 
0 1.58 1.20-2.10 0.001 1.58 1.13-2.21 0.008 
Retrieved from external 
hospital 
0 1.07 0.58-1.97 0.827 - - - 
VA-ECMO insertion 
period  
       
2011-2015 vs.  
2006-2010 
0 0.63 0.35-1.14 0.125 - - - 
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Bold indicates statistical significance. ALT, alanine aminotransferase; AMI, acute myocardial infarction; BMI, body mass 
index; CI, confidence interval; CPR, cardiopulmonary resuscitation; CS, cardiogenic shock; GFR MDRD, glomerular filtration 
rate modification of diet in renal disease; INR, international normalized ratio; LVEF, left ventricular ejection fraction; MAP, 
mean arterial pressure; MD, Missing data; OR, odds ratio; PCI, percutaneous coronary intervention; Ref., reference; VA-
ECMO, venoarterial extracorporeal membrane oxygenation; WBC, white blood cell counts. *Acute decompensated heart 
failure (n = 29), intoxication (n = 3), acute pulmonary embolus (n = 3), drowning (n = 1), endocarditis (n = 1). †Prior to current 
medical event/admission. ‡Just before cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, 
milrinone, levosimendan. 
In the multivariable logistic regression analysis, only three of the independent variables made 
a unique statistical significant contribution to the model (Table 4B) with the most significant 
being arterial lactate (odds ratio [OR] per mmol/L: 1.14; 95% confidence interval [CI]: 1.06-
1.23, p <0.001), followed by the number of inotropes and vasopressors just before cannulation 
(OR per one agent: 1.58; 95% CI: 1.13- 2.21; p = 0.008), and the presence of IHD (OR: 2.90; 
95% CI: 1.31-6.39; p = 0.008). The full model, containing all independent predictors, was 
statistical significant, χ² (7, n = 181) = 60.979; p <0.001, indicating that the model was able to 
distinguish between survivors and non-survivors at 90-days. The χ² for Hosmer-Lemeshow’s 
Test was 10.256 with a significance level of p = 0.247 thereby supporting our model. The 
model as a whole explained between 28.6% (Cox and Snell R2) and 38% (Nagelkerke R2) of 
the variance of 90-day mortality and correctly classified 75% of cases. The sensitivity of the 
model was 78% (the true positives) and its specificity was 71% (the true negatives), giving a 
positive predictive value of 76% and a negative predictive value of 74%. 
TABLE 4B. Factors associated with mortality at 90 days after VA-ECMO initiation 
  Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
Arterial lactate (mmol/L)‡ 0 1.15 1.09-1.21 <0.001 1.14 1.06-1.23 <0.001 
No. of inotropes and 
vasopressors‡§ 
0 1.58 1.20-2.10 0.001 1.58 1.13-2.21 0.008 
Ischemic heart disease 0 3.13 1.70-5.80 <0.001 2.90 1.31-6.39 0.008 
Bold indicates statistical significance. CI, confidence interval; MAP, mean arterial pressure; MD, missing data; OR, odds 
ratio; VA-ECMO, venoarterial extracorporeal membrane oxygenation. ‡Just before cannulation. §Epinephrine, 
norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan. 
 
Regarding the possible significance of cannulation site, type of VA-ECMO cannulation 
(peripheral and central VA-ECMO cannulation in 85% [n = 153] and 15% [n = 28] of 
patients, respectively), surgical cannulation technique (surgical cut down or percutaneous 
approach) and the presence of distal perfusion catheter (71% of patients [n = 128] with 
peripheral cannulation) for 90-day mortality, these factors were not included in the statistical 
analysis as they are considered after the decision has been made to initiate VA-ECMO. The 
aim of Study I was to identify specifically pre-implant predictors for 90-day mortality by not 
mixing pre-implant with implant and post-implant factors (to potentially provide tools to 
clinicians deciding whether to institute VA-ECMO) which otherwise would have included 
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also other factors than the above-mentioned. However, for clarification, the difference between 
survivors and non-survivors and the logistic regression analysis were non-significant regarding 
cannulation site or type of cannulation, as presented in Table 5A and Table 5B.  
TABLE 5A. Cannulation sites and comparison between survivors and non-survivors at 90 days after VA-
ECMO initiation 
Cannulation sites MD (%) All patients  
(n = 181) 
Survivors 
(n = 84) 
Non-survivors  
(n = 97) 
P value 
Operating room 0 146 (81) 66 (45) 80 (55) 0.507 
Catherization laboratory 0 13 (7.2) 5 (38) 8 (62) 0.551 
Intensive care unit  0 22 (12) 13 (59) 9 (41) 0.203 
MD, missing data; VA-ECMO, venoarterial extracorporeal membrane oxygenation. 
 
 
TABLE 5B. Cannulation site associated with 90 day mortality after VA-ECMO initiation 
 Univariable logistic regression  Multivariable logistic regression 
Cannulation sites MD (%) OR 95% CI P value OR 95%CI P value 
Operating room 0 1.28 0.61-2.67 0.508 - - - 
Catherization laboratory 0 1.42 0.45-4.52 0.553 - - - 
Intensive care unit 0 0.56 0.23-1.38 0.208 - - - 
CI, confidence intreval; MD missing data; OR, odds ratio; VA-ECMO, venoarterial extracorporeal membrane oxygenation 
 
Outcome data including events on and after VA-ECMO and causes of death within 90 days 
after initiation of VA-ECMO support are presented in Table 6. The median duration on VA-
ECMO was 7 days (IQR: 3-13). Death during VA-ECMO support occurred in 46% (n = 84) 
of the patients, 45% (n = 82) were successfully weaned, 8% (n = 15) did not tolerate weaning 
whereof 11 patients (6%) were bridged to heart transplantation and 4 patients (2%) were 
bridged to LVAD. The in-hospital mortality was 54% (n = 97) and 46% (n = 84) were 
discharged to home. The overall 90-day mortality after initiation of VA-ECMO was 54% (n = 
97). Multiorgan failure was the main cause of death on VA-ECMO (38 of 84 deaths, 45%), as 
well as within 90 days after initiation of VA-ECMO (43 of 97 deaths, 44%).  
TABLE 6. Outcomes 
Variables  MD  
(%) 
All patients  
(n = 181) 
VA-ECMO duration (days)  0 7 (3-13; 0.02-55) 
Acute myocardial infarction (n = 39) 0 5 (2-10; 0.08-51) 
Postcardiotomy (n = 105) 0 7 (3-14; 0.02-55) 
Other medical* (n = 37) 0 6 (1-15; 0.04-46) 
VA-ECMO destination   
Death during VA-ECMO 0 84 (46) 
Successful weaning  0 82 (45) 
VA-ECMO to heart transplantation   0 11 (6.1) 
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VA-ECMO to LVAD  0 4 (2.2) 
90-day mortality  0 97 (54) 
Acute myocardial infarction (n = 39) 0 20 (51) 
Postcardiotomy (n = 105) 0 60 (57) 
Other medical (n = 37) 0 17 (46) 
In-hospital mortality, non-discharged  0 97 (54) 
Acute myocardial infarction (n = 39) 0 20 (51) 
Postcardiotomy (n = 105) 0 59 (56) 
Other medical* (n = 37) 0 18 (49) 
Discharge to home 0 84 (46) 
Acute myocardial infarction (n = 39) 0 19 (49) 
Postcardiotomy (n = 105) 0 46 (44) 
Other medical* (n = 37) 0 19 (51) 
Days from VA-ECMO initiation to discharge home 0 57 (35-97; 13-295) 
Main cause of death during VA-ECMO  0 84 (46) 
Multiorgan failure 0 38 (21) 
Neurologic† 0 23 (13) 
Cardiac‡ 0 10 (5.5) 
Bleeding§  0 10 (5.5) 
Miscellaneous¶ 0 3 (1.7) 
Main cause of death within 90 days  0 97 (54) 
Multiorgan failure 0 43 (24) 
Neurologic†  0 26 (14) 
Cardiac‡  0 13 (7.2) 
Bleeding§ 0 10 (5.5) 
Miscellaneous¶¥ 0 5 (2.8) 
Categoric and continuous variables are presented as n (%) and median (IQR); range), respectively. LVAD, left ventricular 
assist device; MD, missing data; VA-ECMO, venoarterial extracorporeal membrane oxygenation; *Other medical etiologies: 
acute decompensated heart failure (n = 29), intoxication (n = 3), acute pulmonary embolus (n = 3), drowning (n = 1), 
endocarditis (n = 1). †Stroke, fatal anoxia, brain death. ‡Sudden cardiac arrest, arrhythmia, myocardial infarction, heart failure. 
§Lung, gastrointestinal, and retroperitoneal bleeding. ¶Acute decompensated heart failure not being a candidate for combined 
heart-lung transplantation (n = 1), iatrogenic air entry into the VA-ECMO-circuit (n = 1), aortic dissection secondary to initial 
peripheral cannulation (n = 1). ¥Acute massive pulmonary embolism (n = 1), acute pulmonary embolism and ischemic colitis 
(n = 1). 
 
 
Figure 2 illustrates the cumulative Kaplan-Meier survival curve until 90 days after initiation 
of VA-ECMO support in 181 patients with refractory cardiogenic shock.  
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FIGURE 2. Kaplan Meier survival curve until 90 days after venoarterial extracorporeal membrane oxygenation 
(VA-ECMO) initiation in 181 patients with refractory cardiogenic shock.  
 
Figure 3 depicts the cumulative Kaplan-Meier survival curves until 90 days related to (A) 
arterial lactate intervals, (B) numbers of inotropes and vasopressors, and (C) presence of IHD 
before VA-ECMO initiation in 181 patients with refractory cardiogenic shock. Each of the 
three variables presented a significant drop in survival, most prominent already within the first 
10-20 days after initiation of VA-ECMO. The subgroups of arterial lactate intervals and 
number of inotropes and vasopressors both indicated that the higher the number of agents and 
the higher the arterial lactate level, the worse the 90-day outcome. 
 
 
FIGURE 3. Independent pre-VA-ECMO predictors of 90-day mortality. Kaplan-Meier survival curves until 90 
days after VA-ECMO initiation related to (A) arterial lactate intervals, (B) numbers of inotropes and vasopressors, 
and (C) presence of ischemic heart disease just before VA-ECMO initiation in 181 patients with refractory 
cardiogenic shock. No. of inotropes & vasopressors, epinephrine, norepinephrine, dobutamine, dopamine, 
vasopressin, milrinone, levosimendan; VA-ECMO, venoarterial extracorporeal membrane oxygenation. 
 
The main complications after initiation of VA-ECMO are presented in Figure 4 for 
descriptive purposes but not included in the statistical analysis as they were not pre-VA-
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ECMO factors. The most frequent post-implant complication being renal failure necessitating 
hemodialysis (60%), pneumonia (51%), and sepsis (24%). Moreover, two out of the 181 
patients (1.1%) received left ventricular decompression by placement of a transseptal left atrial 
cannula during VA-ECMO. Both patients died on VA-ECMO. However, left ventricular 
decompression during VA-ECMO is an on-VA-ECMO variable, and was therefore not 
included in the analyses of this thesis. 
 
 
 
FIGURE 4. Main complications after venoarterial extracorporeal membrane oxygenation initiation in 181 
patients with refractory cardiogenic shock.  
 
4.2 STUDY II 
Table 7 presents the pre-VA-ECMO variables and the comparison between survivors and non-
survivors at 90-days after VA-ECMO initiation. Median age was 62 years (IQR: 52-68). This 
was significantly lower in survivors (60 years; IQR: 49-66) compared with non-survivors (65 
years; IQR: 54-69; p = 0.017). In contrast to the other surgical subgroups, only isolated CABG 
differed significantly between survivors and non-survivors, with a 90-day mortality of 86%. 
AMI and IHD was found in 27% (n = 28) and 57% (n = 60) of the patients with an 82% and 
77% 90-day mortality, respectively. Median LVEF, arterial pH and MAP just before 
cannulation were significantly lower among non-survivors compared with survivors. In 
contrast, age, euroSCORE II, prior CABG, arterial lactate, alanine aminotransferase (ALT) 
and total number of inotropes and vasopressors (epinephrine, norepinephrine, dobutamine, 
dopamine, vasopressin, milrinone, levosimendan) were significantly higher among non-
survivors compared with survivors.  
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TABLE 7. Comparison of pre-VA-ECMO characteristics between survivors and non-survivors at 90 days after 
VA-ECMO initiation 
Pre-VA-ECMO 
characteristics 
MD 
(%) 
All patients 
(n = 105)  
Survivors  
(n = 45) 
Non-survivors  
(n = 60) 
P value 
Male gender 0 80 (76) 33 (41) 47 (59) 0.552 
Age (y) 0 62 (52-68; 18-77) 60 (49-66; 18-72) 65 (54-69; 23-77) 0.017 
≥65 (y) 0 42 (40) 13 (31) 29 (69) 0.044 
Weight (kg) 0 80 (72-93; 45-143) 84 (74-93; 45-143) 78 (72-94; 56-130) 0.441 
BMI (kg/m2) 0 26.2 (23.7-29.8) 26.5 (23.6-30.2) 25.9 (23.7-29.5) 0.669 
euroSCORE II score 0 7.32 (2.82-25.03; 
0.62-77.53) 
4.82 (2.19-21.97; 
0.62-43.52) 
10.04 (3.53-28.43; 
0.92-78.53) 
0.046 
euroSCORE II critical 
preoperative state  
0 38 (36) 16 (42) 22 (58) 0.907 
euroSCORE II type of 
cardiac surgical subgroup 
     
Single non-CABG 0 30 (29) 16 (53) 14 (47) 0.170 
Isolated CABG  0 21 (20) 3 (14) 18 (86) 0.003 
2 procedures* 0 33 (31) 16 (49) 17 (51) 0.582 
3 procedures* 0 21 (20) 10 (48) 11(52) 0.622 
euroSCORE II urgency of 
surgery 
     
Elective 0 48 (46) 25 (52) 23 (48) 0.080 
Urgent 0 19 (18) 8 (42) 11 (58) 0.942 
Emergency 0 27 (26) 9 (33) 18 (67) 0.246 
Salvage 0 11 (11) 3 (27) 8 (73) 0.345 
Type of cardioplegia      
No cardioplegia  0 14 (13) 7 (50) 7 (50) 0.562 
Antegrade cardioplegia 0 43 (41) 17 (40) 26 (60) 0.817 
Antegrade + retrograde 
cardioplegia 
0 43 (41) 19 (44) 24 (56) 0.819 
Retrograde cardioplegia 0 5 (4.8) 2 (40) 3 (60) 1.000 
Cross-clamp time (min) 2.9 122 (59-198; 21-359) 136 (84-201; 24-359) 98 (55-193; 21-291) 0.162 
CPB time (min) 2.9 222 (172-283; 35-
568) 
217 (185-275; 35-
556) 
227 (167-287; 81-
568) 
0.869 
From CPB direct to  
VA-ECMO in the OR 
0 51 (49) 21 (41) 30 (59) 0.735 
AMI 0 28 (27) 5 (18) 23 (82) 0.002 
Ischemic heart disease 0 60 (57) 14 (23) 46 (77) <0.001 
Smoking  0 54 (51) 20 (37) 34 (63) 0.215 
Hypertension 0 51 (49) 20 (39) 31 (61) 0.464 
Valvular heart disease  0 72 (69) 34 (47) 38 (53) 0.182 
Congestive heart failure 0 32 (31) 14 (44) 18 (56) 0.903 
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Diabetes mellitus 0 17 (16) 5 (29) 12 (71) 0.221 
Atrial fibrillation 0 26 (25) 9 (35) 17 (65) 0.328 
Dyslipidemia 0 36 (34) 13 (36) 23 (64) 0.313 
Prior† myocardial 
infarction 
0 20 (19) 6 (30) 14 (70) 0.197 
Prior† PCI 0 11 (10) 3 (27) 8 (73) 0.345 
Prior† cardiac surgery 0 28 (27) 10 (36) 18 (64) 0.372 
Prior† CABG   0 12 (11) 2 (17) 10 (83) 0.040 
Chronic renal failure 0 14 (13) 4 (29) 10 (71) 0.246 
Hypertrophic 
cardiomyopathy 
0 14 (13) 4 (29) 10 (71) 0.246 
Endocarditis 0 8 (7.6) 5 (62) 3 (38) 0.243 
Primary graft failure after 
heart transplantation 
0 7 (6.7) 4 (57) 3 (43) 0.232 
Acute pulmonary 
embolism 
0 2 (1.9) 1 (50) 1 (50) 1.000 
LVEF (%)‡ 0 25 (13-50) 33 (18-55) 15 (0-29) <0.001 
<20 (%) 0 50 (48) 12 (24) 38 (76) <0.001 
MAP (mmHg)‡ 0 50 (40-64) 60 (49-68) 47 (40-60) 0.001 
<50 (mmHg) 0 44 (42) 11 (25) 33 (75) 0.002 
Arterial pH‡ 0 7.26 (7.13-7.32; 
6.75-7.49) 
7.29 (7.18-7.35; 
6.84-7.46) 
7.22 (7.09-7.31; 
6.75-7.49) 
0.009 
Arterial lactate (mmol/L)‡ 0 7.0 (3.2-11.5;  
0.7-28.0) 
4.0 (2.0-8.6;  
0.7-14.7) 
8.0 (5.4-14.9;  
0.7-28.0) 
<0.001 
<5 (mmol/L) 0 39 (37) 25 (64) 14 (36) - 
5-9.9 (mmol/L) 0 36 (34) 16 (44) 20 (56) - 
10-14.9 (mmol/L) 0 16 (15) 4 (25) 12 (75) - 
≥15 (mmol/L) 0 14 (13) 0 (0) 14 (100) <0.001 
Hemoglobin (g/L)‡  93 (86-106) 94 (85-109) 93 (86-104) 0.964 
WBC (109/L) 0 10.8 (7.2-15.7) 10.4 (7.2-16.7) 11.2 (7.2-14.8) 0.568 
Platelets (109/L) 0 161 (95-234) 157 (108-228) 161 (87-240) 0.991 
Creatinine (µmol/L)  0 120 (92-169) 110 (79-159) 124 (95-189) 0.103 
GFR MDRD 
(mL/min/1.73m2) 
0 55 (37-73) 62 (41-89) 53 (33-70) 0.074 
ALT (µkat/L) 5.7 0.82 (0.40-2.11) 0.69 (0.34-1.32) 1.06 (0.54-2.80) 0.041 
Pre-VA-ECMO 
interventions 
     
Acute PCI 0 7 (6.7) 2 (29) 5 (71) 0.696 
Hemodialysis 0 24 (23) 10 (42) 14 (58) 0.893 
CPR 0 31 (30) 12 (39) 19 (61) 0.578 
Intra-aortic balloon 
pump 
0 5 (4.8) 1 (20) 4 (80) 0.389 
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No. of inotropes and 
vasopressors‡§ 
0 3 (2-4) 2 (2-3) 3 (2-4) 0.046 
Retrievel from external 
hospital 
0 24 (23) 8 (33) 16 (67) 0.283 
VA-ECMO insertion 
period¶  
     
2006-2010  0 55 (52) 19 (35) 36 (65) - 
2011-2015  0 50 (48) 26 (52) 24 (48) 0.071 
Bold indicates statistical significance. Categoric variables are presented as n (%) and compared with the chi-square, 
likelihood ratio, or Fisher exact test. Continuous variables are presented as median (IQR; range) and compared with the 
Mann–Whitney U test. ALT, alanine aminotransferase; AMI, acute myocardial infarction; BMI, body mass index; CABG, 
coronary artery bypass grafting; CPB, cardiopulmonary bypass; CPR; cardiopulmonary resuscitation; euroSCORE, European 
System for Cardiac Operative Risk Evaluation; GFR MDRD, glomerular filtration rate modification of diet in renal disease; 
LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; MD, missing data; OR operating room; PCI, 
percutaneous coronary intervention; VA-ECMO, venoarterial membrane oxygenation; WBC, white blood cell counts. *Number 
of surgical interventions on the heart (euroSCORE II classification). †Prior to current medical event/admission. ‡Just before 
cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan. ¶Postimplant 
variable only for descriptive purposes. 
 
Univariable logistic regression identified 8 variables that were significantly associated with 
90-day mortality: age, isolated CABG, AMI, IHD, LVEF, MAP, arterial pH and lactate (Table 
8A). Arterial pH and lactate correlated strongly (rho = - 0.713; p <0.001), as did AMI and IHD 
(rho = 0.522; p <0.001), CABG and IHD (rho = 0.433; p <0.001), and CABG and AMI (rho 
= 0.829; p <0.001), respectively. AMI and CABG, both included in the variable IHD, together 
with arterial pH were excluded from the model. This left five variables in the model. We 
favored exclusion of pH and not lactate, as lactate can be considered to be a more robust 
variable as it is less sensitive to the influence of PaC02 and administration of buffer solutions 
in the emergency setting. 
TABLE 8A. Factors associated with mortality within 90 days after VA-ECMO initiation 
 Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR  95% CI P value OR 95% CI P value 
Male gender 0 1.32 0.53-3.24 0.552 - - - 
Age (y) 0 1.04 1.01-1.07 0.017 1.04 0.99-1.09 0.058 
≥65 vs. <65 (y) 0 2.30 1.01-5.23 0.046 - - - 
Weight (kg) 0 1.00 0.98-1.02 0.970 - - - 
BMI (kg/m2) 0 0.99 0.92-1.07 0.800 - - - 
euroSCORE II 0 1.03 0.99-1.05 0.071 - - - 
euroSCORE II critical 
preoperative state  
0 1.05 0.47-2.35 0.907 - - - 
euroSCORE II type of 
cardiac surgery  
       
Single non-CABG 0 0.55 0.24-1.30 0.173 - - - 
Isolated CABG 0 6.00 1.64-21.9 0.007 - - - 
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2 procedures* 0 0.72 0.31-1.64 0.431 - - - 
3 procedures* 0 0.62 0.30-2.05 0.622 - - - 
euroSCORE II urgency 
of surgery 
       
Elective 0 0.50 0.23-1.09 0.081 - - - 
Urgent 0 1.04 0.38-2.84 0.942 - - - 
Emergency 0 1.71 0.69-4.28 0.249 - - - 
Salvage 0 2.15 0.54-8.63 0.279 - - - 
Type of cardioplegia        
No cardioplegia  0 Ref. - - - - - 
Antegrade cardioplegia 0 1.53 0.46-5.14 0.492 - - - 
Antegrade + retrograde  
cardioplegia 
0 1.26 0.38-4.23 0.705 - - - 
Retrograde 
cardioplegia 
0 1.50 0.19-11.93 0.702 - - - 
Cross clamp time (min) 2.9 1.00 0.99-1.00 0.206 - - - 
CPB time (min) 2.9 1.00 0.99-1.00 0.738 - - - 
From CPB direct to  
VA-ECMO in the OR 
0 1.14 0.53-2.48 0.735 - - - 
AMI 0 4.97 1.71-14.4 0.003 - - - 
Ischemic heart disease 0 7.28 3.05-17.4 <0.001 7.87 2.55-24.3 <0.001 
Smoking  0 1.64 0.75-3.56 0.216 - - - 
Hypertension 0 1.33 0.62-2.90 0.464 - - - 
Valvular heart disease  0 0.56 0.24-1.32 0.184 - - - 
Congestive heart failure 0 0.95 0.41-2.20 0.903 - - - 
Diabetes mellitus 0 2.00 0.65-6.16 0.227 - - - 
Atrial fibrillation 0 1.58 0.63-3.97 0.330 - - - 
Dyslipidemia 0 1.53 0.67-3.50 0.314 - - - 
Prior† myocardial 
infarction 
0 1.98 0.69-5.64 0.202 - - - 
Prior† PCI 0 2.15 0.54-8.63 0.279 - - - 
Prior† cardiac surgery 0 1.50 0.61-3.67 0.374 - - - 
Prior† CABG 0 4.30 0.89-20.7 0.069 - - - 
Chronic renal failure 0 2.05 0.60-7.02 0.253 - - - 
Hypertrophic 
cardiomyopathy 
0 2.05 0.60-7.02 0.253 - - - 
Endocarditis 0 0.42 0.10-1.86 0.254 - - - 
Primary graft failure after 
heart transplantation 
0 0.54 0.12-2.54 0.435 - - - 
LVEF (%)‡ 0 0.96 0.94-0.98 <0.001 0.98 0.95-1.01 0.112 
<20 vs. ≥20 (%) 0 4.75 2.04-11.1 <0.001 - - - 
MAP (mmHg)‡ 0 0.96 0.94-0.99 0.007 0.98 0.95-1.04 0.243 
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<50 vs. ≥50 (mmHg) 0 3.78 1.62-8.83 0.002 - - - 
Arterial pH‡ 0 0.03 0.00-0.53 0.017 - - - 
Arterial lactate (mmol/L)‡ 0 1.21 1.10-1.33 <0.001 1.22 1.07-1.40 0.004 
Hemoglobin (g/L)‡ 0 1.00 0.98-1.02 0.851 - - - 
WBC (109/L) 0 0.97 0.93-1.02 0.269 - - - 
Platelets (109/L) 0 1.00 0.99-1.00 0.576 - - - 
Creatinine (µmol/L)  0 1.00 0.99-1.01 0.686 - - - 
GFR MDRD 
(mL/min/1.73m2) 
0 0.99 0.97-1.00 0.051 - - - 
ALT (µkat/L) 5.7 1.00 0.97-1.04 0.923 - - - 
Pre-VA-ECMO 
interventions 
0       
Acute PCI 0 1.96 0.36-10.6 0.436 - - - 
Hemodialysis 0 1.07 0.42-2.68 0.893 - - - 
CPR  0 1.27 0.54-3.00 0.579 - - - 
No. of inotropes and 
vasopressors‡§ 
0 1.42 0.99-2.04 0.055 - - - 
Retrieval from external 
hospital 
0 1.68 0.65-4.37 0.286 - - - 
Bold indicates statistical significance. ALT, alanine aminotransferase; AMI, acute myocardial infarction; BMI, body mass 
index; CABG, coronary artery bypass grafting; CI, confidence interval; CPB, cardiopulmonary bypass; CPR, cardiopulmonary 
resuscitation; euroSCORE, European System for Cardiac Operative Risk Evaluation; GFR MDRD, glomerular filtration rate 
modification of diet in renal disease; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; MD, missing data; 
OR, odds ratio; OR operating room; PCI, percutaneous coronary intervention; VA-ECMO, venoarterial membrane 
oxygenation; WBC, white blood cell counts. *Number of surgical interventions on the heart (euroSCORE II classification). 
†Prior to current medical event/admission. ‡Just before cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, 
vasopressin, milrinone, levosimendan. 
 
When determining AIC, the original model had a value of 102, compared to 105 (3 knots) and 
104 (4 knots). The corresponding BIC values were 118, 131 (3 knots), and 141 (4 knots), 
respectively. Due to comparable values in both AIC and BIC, the approach of non-linearity 
through splines did thereby not influence the logistic regression analysis unacceptably. This 
supported the original model without transformations, which thereby facilitates clinical 
interpretation of the findings. The model was statistically significant, χ² (5, n = 105) = 52.911; 
p <0.001, indicating that the original model appropriately could discriminate between 
survivors and non-survivors at 90-days after initiation of VA-ECMO. χ² for Hosmer-
Lemeshow’s Test was 2.952 with a significance level of p = 0.937. This further supported that 
the overall fit of the model was sufficient. The model as a whole explained between 40% (Cox 
and Snell R2) and 53% (Nagelkerke R2) of the variance of 90-day mortality and overall 
correctly classified 80% of the cases. The original model’s sensitivity and specificity was 85% 
(true positives) and 73% (true negatives), respectively, resulting in a positive predictive value 
of 81% and a negative predictive value of 79%. 
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Two of the independent variables significantly contributed to the model (Table 8B) in 
multivariable logistic regression analysis. Presence of IHD was the most significant predictor 
of 90-day mortality (OR: 7.87; 95% CI: 2.55-24.3; p <0.001), followed by arterial lactate (OR 
per mmol/L increase: 1.22; 95% CI: 1.07-1.40, p = 0.004).  
TABLE 8B. Factors associated with mortality at 90 days after VA-ECMO initiation 
  Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
Age (y) 0 1.04 1.01-1.07 0.017 1.04 0.99-1.09 0.058 
Ischemic heart disease 0 7.28 3.05-17.4 <0.001 7.87 2.55-24.3 <0.001 
LVEF (%)‡ 0 0.96 0.94-0.98 <0.001 0.98 0.95-1.01 0.112 
MAP (mmHg)‡ 0 0.96 0.94-0.99 0.007 0.98 0.95-1.04 0.243 
Arterial lactate (mmol/L)‡ 0 1.21 1.10-1.33 <0.001 1.22 1.07-1.40 0.004 
Bold indicates statistical significance. CI, confidence interval; LVEF, left ventricular ejection fraction; MAP, mean arterial 
pressure; MD, missing data; OR, odds ratio; VA-ECMO, venoarterial membrane oxygenation. ‡Just before cannulation.  
 
Table 9 demonstrates outcome data including events after initiation of VA-ECMO and causes 
of death within 90 days. The median duration of VA-ECMO was 7 days (IQR: 3-14). Forty-
nine patients (47%) died during VA-ECMO, 54 patients (51%) were successfully weaned, two 
patients (2%) could not be weaned, one patient (1%) was bridged to heart transplantation and 
one patient (1%) was bridged to LVAD. The in-hospital mortality was 56% (n = 59) and 44% 
(n = 46) were discharged home. The median number of days from initiation of VA-ECMO to 
discharge home was 64 (IQR: 41-105; range 13-212). The overall 90-day mortality after 
initiation of VA-ECMO, which was the primary endpoint, was 57% (n = 60). The overall 
mortality at 24, 48, 72 hours, 7, and 30 days were 11%, 11%, 15%, 25% and 51%, respectively.  
Multiorgan failure was the main cause of death both on VA-ECMO (24 of 49 deaths, 49%) 
and within 90 days after its initiation (29 of 49 deaths, 59%). The 90-day mortality in patients 
with peripheral (76%, n = 80) and central cannulation (24%, n = 25) was 51% and 76%, 
respectively. Seventy-two patients (90%) with peripheral cannulation received an extra distal 
perfusion cannula for antegrade perfusion of the leg (shunt).  
TABLE 9. Outcomes 
Variables  MD  
(%) 
All patients  
(n = 105) 
VA-ECMO duration (days) 0 7 (3-14; 1-55) 
Single non-CABG (n = 30) 0 8 (4-25) 
Isolated CABG (n = 21) 0 6 (2-11) 
2 Procedures* (n = 33) 0 9 (5-17) 
3 Procedures* (n = 21) 0 5 (3-11) 
VA-ECMO destination   
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Death during VA- ECMO 0 49 (47) 
Successful weaning  0 54 (51) 
VA-ECMO to heart transplantation   0 1 (1.0) 
VA-ECMO to LVAD  0 1 (1.0) 
90-day mortality  0 60 (57) 
Single non-CABG (n = 30) 0 14 (47) 
Isolated CABG (n = 21) 0 18 (86) 
2 Procedures* (n = 33) 0 17 (52) 
3 Procedures* (n = 21) 0 11 (52) 
In-hospital mortality 0 59 (56) 
Single non-CABG (n = 30) 0 13 (43) 
Isolated CABG (n = 21) 0 18 (86) 
2 Procedures* (n = 33) 0 17 (52) 
3 Procedures* (n = 21) 0 11 (52) 
Discharge to home 0 46 (44) 
Single non-CABG (n = 30) 0 17 (57) 
Isolated CABG (n = 21) 0 3 (14) 
2 Procedures* (n = 33) 0 16 (49) 
3 Procedures* (n = 21) 0 10 (48) 
Days from VA-ECMO initiation to discharge home 0 64 (41-105; 13-212) 
CPC score at discharge to home 0 46 (44) 
CPC 1-2 0 46 (100) 
CPC 3-4 0 0 (0) 
Main cause of death during VA-ECMO  0 49 (47) 
Multiorgan failure 0 24 (23) 
Neurologic† 0 9 (8,6) 
Cardiac‡ 0 7 (6.7) 
Bleeding§ 0 7 (6.7) 
Miscellaneous¶ 0 2 (1.9) 
Main cause of death within 90 days  0 60 (57) 
Multiorgan failure 0 29 (28) 
Neurologic† 0 12 (11) 
Cardiac‡  0 8 (7.6) 
Bleeding§  0 7 (6.7) 
Miscellaneous¶,¥ 0 4 (3.8) 
Categorical and continuous variables are presented as n (%) and median (interquartile range (IQR); range), respectively. 
CABG, coronary artery bypass grafting; CPC, cerebral performance category; LVAD, left ventricular assist device; MD, 
missing data; VA-ECMO, venoarterial extracorporeal membrane oxygenation. *Number of surgical interventions on the 
heart (euroSCORE II classification). †Stroke, fatal anoxia, brain death. ‡Sudden cardiac arrest, arrhythmia, myocardial 
infarction, heart failure. §Lung, gastrointestinal, retroperitoneal bleeding. ¶Iatrogenic air entry into the VA-ECMO-circuit 
(n = 1), aortic dissection at cannulation (n = 1). ¥Massive pulmonary embolus (n = 1), pulmonary embolus and ischemic 
colitis (n = 1). 
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The cumulative Kaplan-Meier survival curves until 90 days after initiation of VA-ECMO 
related to arterial lactate intervals are presented in Figure 5A, which suggests that an arterial 
lactate level ≥10 mmol/L (90.1 mg/dL) had severely worse outcome (p <0.001). All patients 
with an arterial lactate level 15 mmol/L (135 mg/dL) died within 20 days after VA-ECMO 
initiation. The cumulative 90-day survival in patients with IHD was 23% compared with 69% 
in patients without IHD (p <0.001) (Figure 5B). 
FIGURE 5. Kaplan-Meier survival curves until 90 days after VA-ECMO initiation related to (A) arterial lactate 
intervals, and (B) presence of ischemic heart disease, with 95% confidence intervals, at initiation of VA-ECMO 
in 105 patients with refractory postcardiotomy cardiogenic shock.  
The surgical euroSCORE II subgroup isolated CABG, despite not being an independent risk 
factor of 90-day mortality, had the poorest survival, with a rapid fall during the first 15 days 
after which it flattened to 14% at 90 days after start of VA-ECMO (p <0.001). Conversely, 90-
day survival rates of the remaining three euroSCORE II subgroups (single non-CABG, 2- and 
3 concomitant surgical procedures) were close to 50% as illustrated in Figure 6. 
 
FIGURE 6. Kaplan-Meier survival curves until 90 days after VA-ECMO initiation related to euroSCORE II 
classification: single non-CABG, 2- and 3 concomitant surgical procedures and isolated CABG, in 105 patients 
with refractory postcardiotomy cardiogenic shock.  
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Figure 7 depicts the main complications after VA-ECMO initiation. Renal failure 
necessitating hemodialysis was the most frequent complication (70%) followed by re-
exploration (68%), pneumonia (61%), sepsis (24%), and ischemic stroke (16%).  
 
 
FIGURE 7.  Main complications after venoarterial extracorporeal membrane oxygenation initiation in 105 
patients with refractory postcardiotomy cardiogenic shock. PSM, poststernotomy mediastinitis. 
 
STUDY III 
A comparison of pre-VA-ECMO variables between survivors and non-survivors of 76 non-
surgical patients at 90 days after initiation of VA-ECMO support is presented in Table 10. 
There were significant differences including arterial lactate, arterial pH, MAP, and number of 
inotropes and vasopressors just before cannulation. Median age was 52 years (IQR: 37-60) 
and did not differ significantly between survivors (50 years; IQR: 36-58) and non-survivors 
(55 years; IQR: 47-60; p = 0.194). Three patients were older than 70 years (the oldest was 76 
years old), all being alive at 90 days after VA-ECMO initiation. The most common etiology 
(mutually exclusive) for VA-ECMO support was AMI (n = 39; 51%) followed by AHF of 
other etiologies (n = 37; 49%); acute deterioration of chronic cardiomyopathy (n = 13; 17% 
including idiopathic non-ischemic cardiomyopathy [n = 9; 12%] and ischemic 
cardiomyopathy [n = 4; 5.3%]), acute myocarditis (n = 10; 13%), acute pulmonary embolus 
(n = 3; 4%), intoxication (n = 3; 4%), septic cardiomyopathy (n = 3; 4%), peripartum 
cardiomyopathy (n = 2; 2.6%), severe hypothermia (n = 1; 1.3%), endocarditis (n = 1; 1.3%), 
and congenital pulmonary valve stenosis (n = 1; 1.3%). Before VA-ECMO implantation, CPR, 
primary PCI, and support with intra-aortic balloon pump (IABP) was performed in 47% (n = 
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36), 54% (n = 41) and 24% (n = 18) of patients, respectively. IABP was removed in 10 patients 
(13%) at VA-ECMO initiation, leaving 8 patients (11%) with IABP during VA-ECMO 
support. Seven patients (9%) received renal replacement therapy (RRT) before initiation of 
VA-ECMO and in further 22 patients (29%) RRT was started during VA-ECMO, resulting in 
totally 35 patients (46%) receiving RRT during VA-ECMO. Mechanical ventilation was 
applied before implantation in all patients (n = 76). The location of cannulation did not 
significantly influence 90-day mortality, with 47 patients being cannulated in the operating 
room (62%, p = 0.955), 18 in the ICU (24%, p = 0.341), and 11 in the catheterization laboratory 
(15%, p = 0.283). Seventy-six percent of patients with peripheral cannulation (56 of 74) 
received a distal perfusion catheter.  
TABLE 10. Comparison of pre-VA-ECMO characteristics between survivors and non-survivors at 90 days after 
VA-ECMO initiation 
Pre-VA-ECMO 
characteristics 
MD 
(%) 
All patients 
(n = 76) 
Survivors  
(n = 39) 
Non-survivors  
(n = 37) 
P value 
Male gender 0 56 (74) 28 (50) 28 (50) 0.701 
Age (y) 0 52 (37-60; 11-76) 50 (36-58; 16-76) 55 (47-60; 11-70) 0.194 
Weight (kg)  0 76 (68-92; 39-
110) 
79 (67-92; 50-109) 79 (71-93; 44-126) 0.388 
BMI  0 25.3 (22.7-29.0) 24.6 (22.6-28.6) 26.5 (22.5-29.4) 0.336 
Etiology of refractory CS 
     
AMI 0 39 (51) 19 (49) 20 (51) - 
Other AHF etiologies* 0 37 (49) 20 (54) 17 (46) 0.642 
Acute decompensated 
chronic CMP 
0 13 (17) 8 (62) 5 (38) 0.418  
Acute myocarditis 0 10 (13) 7 (70) 3 (30) 0.311 
Clinical presentation 
     
STEMI 0 36 (47) 18 (50) 18 (50) 0.828 
NSTEMI 0 3 (3.9) 1 (33) 2 (67) 0.610 
Ischemic heart disease 0 42 (55) 21 (50) 21 (50) 0.799 
Single vessel CAD 0 14 (18) 7 (50) 7 (50) 1.000 
Two vessel CAD 0 4 (5.3) 3 (75) 1 (25) 0.615 
Three vessel CAD 0 21 (28) 9 (43) 12 (57) 0.362 
Smoking 0 28 (37) 13 (46) 15 (54) 0.515 
Hypertension 0 22 (29) 10 (46) 12 (54) 0.514 
Valvular heart disease  0 23 (30) 14 (61) 9 (39) 0.272 
Dyslipidemia 0 17 (22) 6 (35) 11 (65) 0.134 
Diabetes mellitus 0 11 (15) 4 (36) 7 (64) 0.283 
Acute myocarditis 0 10 (13) 7 (70) 3 (30) 0.311 
Atrial fibrillation 0 7 (9.2) 3 (43) 4 (57) 0.708 
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Prior† myocardial 
infarction 
0 7 (9.2) 4 (57) 3 (43) 1.000 
Prior† PCI 0 5 (6.6) 2 (40) 3 (60) 0.671 
Prior† CABG  0 5 (6.6) 1 (20) 4 (80) 0.194 
Chronic renal failure 0 3 (3.9) 2 (67) 1 (33) 1.000 
LVEF (%)‡ 0 11 (0-20) 15 (0-20) 0 (0-20) 0.098 
MAP (mmHg)‡ 0 55 (48-65) 60 (50-70) 50 (42-60) 0.015 
Arterial pH‡ 0 7.22 (7.01-7.33; 
6.55-7.57) 
7.29 (7.17-7.37; 
6.63-7.57) 
7.12 (6.90-7.29;  
6.66-7.45) 
0.005 
Arterial lactate (mmol/L)‡ 0 7.7 (2.9-15.8;  
0.4-27.0) 
4.0 (2.2-12.0;  
0.4-20.0) 
13.0 (5.1-18.6; 
0.7-27.0) 
0.002 
<10 (mmol/L) 0 41 (54) 28 (68) 13 (32) - 
10-20 (mmol/L) 0 28 (37) 11 (39) 17 (61) - 
>20 (mmol/L) 0 7 (9.2) 0 (0) 7 (100) <0.001 
Hemoglobin (g/L)‡ 0 118 (99-131) 118 (98-137) 115 (100-128) 0.647 
CRP (mg/L) 9 52 (9-108) 51 (8-98) 54 (9-151) 0.513 
WBC (109/L) 5 12.4 (9.6-17.4) 12.5 (9.8-17.5) 11.1 (9.2-17.9) 0.530 
Platelets (109/L) 2 180 (107-235) 183 (105-226) 177 (110-239) 0.858 
INR 8 1.4 (1.1-1.6) 1.4 (1.1-1.9) 1.4 (1.1-1.6) 0.604 
Creatinine (µmol/L)  2 127 (86-160) 129 (81-148) 126 (87-165) 0.592 
GFR MDRD 
(mL/min/1.73m2) 
2 52 (40-86) 52 (43-87) 52 (36-85) 0.469 
ALT (µkat/L) 8 3.24 (0.90-10.70) 3.61 (0.90-10.58) 3.04 (0.99-11.50) 1.000 
Pre-VA-ECMO 
interventions 
     
Primary PCI 0 36 (47) 17 (47) 19 (53) 0.498 
Successful PCI 0 22 (61) 11 (50) 11 (50) 0.994 
Intra-aortic balloon 
pump 
0 18 (24) 7 (39) 11 (61) 0.227 
CPR  0 41 (54) 19 (46) 22 (54) 0.348 
Hemodialysis 0 7 (9.2) 4 (57) 3 (43) 1.000 
No. of inotropes and 
vasopressors‡§ 
0 2 (2-3) 2 (1-3) 2 (2-3) 0.015 
1 0 17 (22) 13 (77) 4 (23) - 
2 0 33 (43) 16 (48) 17 (52) - 
≥3 0 26 (34) 10 (38) 16 (62) 0.047 
Retrieval from external 
hospital 
0 40 (53) 21 (52) 19 (48) 0.828 
VA-ECMO insertion 
period¶  
     
2006-2010  0 38 (50) 19 (50) 19 (50) - 
2011-2015  0 38 (50) 20 (53) 18 (47) 0.818 
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Bold indicates statistical significance. Categorical variables are presented as numbers (n) and percentages (%), and compared 
with the Chi-square, Likelihood ratio or Fischer’s exact test. Continuous variables are presented as median (interquartile range 
(IQR); range) and compared with the Mann-Whitney U test. AHF, acute heart failure; ALT, alanine aminotransferase; AMI; 
acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; 
CMP, cardiomyopathy; CPR, cardiopulmonary resuscitation; CS, cardiogenic shock; GFR MDRD, glomerular filtration rate 
modification of diet in renal disease; INR, international normalized ratio; LVEF, left ventricular ejection fraction; MAP, mean 
arterial pressure; MD, missing data; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary; 
intervention; STEMI, ST-elevation myocardial infarction; VA-ECMO, venoarterial extracorporeal membrane oxygenation; 
WBC, white blood cell counts.*Acute decompensated chronic cardiomyopathy (n = 13), acute myocarditis (n = 10), 
intoxication, acute pulmonary embolus, septic cardiomyopathy (each n = 3), peripartum cardiomyopathy (n = 2), prolonged 
hypothermia, endocarditis, congenital pulmonary valve stenosis (each n = 1).†Prior to current medical event/admission. ‡Just 
before cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan. 
¶Postimplant variable only for descriptive purposes. 
  
Four variables were found significantly associated with 90-day mortality in the univariable 
logistic regression analysis: arterial lactate, arterial pH, number of inotropes and vasopressors, 
and MAP (Table 11A). Two variables remained significant in the multivariable logistic 
regression analysis, after exclusion of pH and MAP due to high correlation with lactate (rho = 
-0.759; p <0.001 and rho = -0.662; p <0.001, respectively), with the most significant being 
arterial lactate (OR per mmol/L: 1.15; 95% CI: 1.06-1.24; p = 0.001), followed by the number 
of inotropes and vasopressors (OR per agent: 2.14; 95% CI: 1.26-3.63; p = 0.005). 
TABLE 11A. Factors associated with mortality at 90 days after VA-ECMO initiation 
 Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
Male gender  0 1.22 0.44-3.41 0.701 - - - 
Age (y) 0 1.02 0.99-1.05 0.252 - - - 
Weight (kg)  0 1.01 0.98-1.04 0.510 - - - 
BMI  0 1.05 0.95-1.17 0.328 - - - 
Clinical presentation        
AMI 0 1.24 0.50-3.05 0.642 - - - 
STEMI 0 1.11 0.45-2.72 0.828 - - - 
Ischemic heart disease 0 1.13 0.46-2.78 0.799 - - - 
Single vessel CAD 0 1.07 0.33-3.40 0.913 - - - 
Two vessel CAD 0 0.33 0.03-3.36 0.351 - - - 
Three vessel CAD 0 1.60 0.58-4.41 0.364 - - - 
Smoking 0 1.36 0.54-3.47 0.516 - - - 
Hypertension 0 1.39 0.52-3.77 0.515 - - - 
Valvular heart disease  0 0.82 0.29-2.28 0.701 - - - 
Diabetes mellitus 0 2.04 0.54-7.66 0.290 - - - 
Atrial fibrillation 0 1.46 0.30-6.99 0.640 - - - 
Dyslipidemia 0 2.33 0.76-7.13 0.139 - - - 
Prior† myocardial 
infarction 
0 0.77 0.16-3.71 0.747 - - - 
Prior† PCI 0 1.63 0.26-10.4 0.603 - - - 
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Prior† CABG  0 4.61 0.49-43.3 0.181 - - - 
Acute myocarditis 0 0.55 0.15-2.08 0.381 - - - 
Chronic renal failure 0 0.51 0.05-5.92 0.593 - - - 
LVEF (%)‡  0 0.99 0.97-1.01 0.375 - - - 
MAP (mmHg)‡ 0 0.96 0.93-0.99 0.036 - - - 
Arterial pH‡ 0 0.04 0.01-0.37 0.005 - - - 
Arterial lactate (mmol/L)‡ 0 1.12 1.05-1.20 0.002 1.15 1.06-1.24 0.001 
Hemoglobin (g/L)‡ 0 0.99 0.98-1.02 0.863 - - - 
CRP (mg/L) 9 1.00 0.99-1.01 0.216 - - - 
WBC (109/L) 5 0.98 0.92-1.04 0.492 - - - 
Platelets (109/L) 2 1.00 0.99-1.01 0.993 - - - 
INR 8 0.78 0.42-1.44 0.429 - - - 
Creatinine (µmol/L)  2 1.00 0.99-1.01 0.490 - - - 
GFR MDRD 
(mL/min/1.73m2) 
2 0.99 0.99-1.01 0.905 - - - 
ALT (µkat/L) 8 1.01 0.97-1.05 0.596 - - - 
Pre-VA-ECMO 
interventions 
    - - - 
Acute PCI 0 1.37 0.55-3.37 0.499 - - - 
Intra-aortic balloon pump 0 1.06 0.28-4.02 0.929 - - - 
CPR  0 1.54 0.62-3.83 0.349 - - - 
Hemodialysis 0 0.77 0.16-3.71 0.747 - - - 
No. of inotropes and 
vasopressors‡§ 
0 1.82 1.12-2.94 0.015 2.14 1.26-3.63 0.005 
Retrieved from external 
hospital 
0 0.91 0.37-2.23 0.828 - - - 
Bold indicates statistical significance. ALT, alanine aminotransferase; AMI, acute myocardial infarction; BMI, body mass index; 
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CMP, cardiomyopathy; CPR, 
cardiopulmonary resuscitation; GFR MDRD, glomerular filtration rate modification of diet in renal disease; INR, international 
normalized ratio; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; MD, missing data; OR, odds ratio; PCI, 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; WBC, white blood cell counts; VA-ECMO, 
venoarterial extracorporeal membrane oxygenation. †Prior to current medical event/admission. ‡Just before cannulation. 
§Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan. 
 
Non-linearity did not impact the logistic regression analysis according to the restricted cubic 
splines analysis. This favors the use of the model. The original model had a value of 90, 
compared to 93 (3 knots) and 97 (4 knots) when assessing AIC. The corresponding BIC values 
were 97, 105 (3 knots), and 113 (4 knots), respectively. As the values in both AIC and BIC 
were similar, the use of non-linearity through splines did not appear to influence the logistic 
regression analysis in a pugnacious way, thereby supporting the original model without 
transformation and facilitating clinical interpretation. The full model with the independent 
predictors, was statistical significant, χ² (df = 2, n = 76) = 21.433; p <0.001, implying that the 
original model could differ between survivors and non-survivors at 90-days after VA-ECMO 
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initiation. The χ² for Hosmer-Lemeshow’s Test was 6.293 with a significance level of p = 0.614 
which supported the use of the model. Both the independent variables, arterial lactate and 
number of inotropes and vasopressors, contributed significantly to the model as shown in Table 
11B.  The model has a sensitivity of 70% (true positives) and a specificity of 67% (true 
negatives), which positive predictive value of 67% and negative predictive value of 70%. 
 
TABLE 11B. Factors associated with mortality at 90 days after VA-ECMO initiation 
  Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
MAP (mmHg)‡ 0 0.96 0.93-0.99 0.036 - - - 
Arterial pH‡ 0 0.04 0.01-0.37 0.005 - - - 
Arterial lactate (mmol/L)‡ 0 1.12 1.05-1.20 0.002 1.15 1.06-1.24 0.001 
No. of inotropes and 
vasopressors‡§ 
0 1.82 1.12-2.94 0.005 2.14 1.26-3.63 0.005 
Bold indicates statistical significance. CI, confidence interval; MAP, mean arterial pressure; MD, missing data; OR, odds 
ratio; VA-ECMO, venoarterial membrane oxygenation. ‡Just before cannulation. §Epinephrine, norepinephrine, 
dobutamine, dopamine, vasopressin, milrinone, levosimendan. 
 
Table 12 presents the outcome data including events after VA-ECMO initiation and causes 
of death within 90 days. The median duration on VA-ECMO was 5 days (IQR: 2-11; 1-51). 
Thirty-five patients (46%) died during VA-ECMO support, and 28 patients (37%) were 
successfully weaned.  Weaning failed in 13 patients (17%), 10 patients (13%) were bridged 
to heart transplantation, and 3 patients (4%) were bridged to LVAD. The in-hospital 
mortality was 50% (n = 38) and 50% (n = 38) were discharged to home. The mortality rate 
after 24, 48, 72 hours, 7, 30, 90 days, and 18 months were 16%, 22%, 24%, 33%, 42%, 49%, 
and 51%, respectively. Of the 38 patients discharged to home, all had a good cerebral 
functional outcome score, defined as a score of 1-2 according to the Cerebral Performance 
Category (CPC) scale. Multiorgan failure and brain injuries were the main causes of death 
on VA-ECMO, 40% (14 of 35 deaths) respectively, as well as within 90 days after initiation 
of VA-ECMO, 38% (14 of 37 deaths) respectively. 
 
TABLE 12. Outcomes 
Variables MD  
(%) 
All patients  
(n = 76) 
VA-ECMO duration (days) 0 5 (2-11; 1-51) 
AMI (n = 39) 0 5 (2-10) 
Other AHF etiologies* (n = 37) 0 6 (1-15) 
Acute decompensated chronic CMP (n = 13) 0 7 (3-16) 
Myocarditis (n = 10) 0 14 (5-29) 
VA-ECMO destination 
  
Death during VA-ECMO 0 35 (46) 
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Successful weaning  0 28 (37) 
VA-ECMO to heart transplantation   0 10 (13) 
VA-ECMO to LVAD 0 3 (3.9) 
90-day mortality  0 37 (49) 
AMI (n = 39) 0 20 (51) 
Other AHF etiologies* (n = 37) 0 17 (46) 
Acute decompensated chronic CMP (n = 13) 0 5 (38) 
Myocarditis (n = 10) 0 3 (30) 
In-hospital mortality 0 38 (50) 
AMI (n = 39) 0 20 (51) 
Other AHF etiologies* (n = 37) 0 18 (49) 
Acute decompensated chronic CMP (n = 13) 0 5 (38) 
Myocarditis (n = 10) 0 3 (30) 
Discharge to home 0 38 (50) 
Days from VA-ECMO initiation to discharge home 0 46 (33-88;13-295) 
CPC score at discharge to home 0 38 (50) 
CPC 1-2 0 38 (100) 
CPC 3-4 0 0 (0) 
Cause of death during VA-ECMO  0 35 (46) 
Multiorgan failure 0 14 (18) 
Neurological† 0 14 (18) 
Cardiac‡ 0 3 (3.9) 
Bleeding§ 0 3 (3.9) 
Miscellaneous¶ 0 1 (1.3) 
Cause of death within 90 days  0 37 (49) 
Multiorgan failure  0 14 (18) 
Neurological† 0 14 (18) 
Cardiac‡ 0 3 (3.9) 
Bleeding§ 0 5 (6.6) 
Miscellaneous¶ 0 1 (1.3) 
Categorical and continuous variables are presented as numbers (n), percentages (%), and median (interquartile range (IQR); 
range), respectively. AHF, acute heart failure; AMI, acute myocardial infarction; CMP, cardiomyopathy; CPC, cerebral 
performance category; LVAD, left ventricular assist device; MD, missing data; VA-ECMO, venoarterial extracorporeal 
membrane oxygenation. *Acute decompensated chronic cardiomyopathy (n = 13), acute myocarditis (n = 10), intoxication, 
acute pulmonary embolus, septic cardiomyopathy (each n = 3), peripartum cardiomyopathy (n = 2), prolonged hypothermia, 
endocarditis, congenital pulmonary valve stenosis (each n = 1). †Stroke, fatal anoxia, brain death. ‡Sudden cardiac arrest, 
myocardial infarction, heart failure. §Lung, gastrointestinal, retroperitoneal. ¶Terminal emphysema.  
 
The cumulative Kaplan-Meier survival curves until 90 days after initiation of VA-ECMO 
related to the arterial lactate intervals are presented in Figure 8 and suggest that the higher the 
arterial lactate level, the worse the survival (p <0.001). The three curves display a significant 
fall in survival mainly within the first 10 days after VA-ECMO initiation. All patients (7 of 
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7) with a pre-VA-ECMO lactate level higher than 20mmol/L died within six days after 
initiation of VA-ECMO. 
 
 
FIGURE 8. Kaplan-Meier survival curves until 90 days after VA-ECMO initiation related to arterial lactate 
intervals in 76 patients with non-surgical refractory cardiogenic shock. VA-ECMO, venoarterial extracorporeal 
membrane oxygenation. 
 
Figure 9 illustrates the main complications after initiation of VA-ECMO with the most 
frequent being renal failure necessitating hemodialysis (46%), pneumonia (38%), sepsis 
(25%), and brain death or fatal anoxia (16%). 
 
 
FIGURE 9. Main complications after venoarterial extracorporeal membrane oxygenation initiation in 76 
patients with non-surgical refractory cardiogenic shock.  
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4.3 STUDY IV 
 
Seventy-two patients who received VA-ECMO following cardiac arrest with CPR duration 
>1 minute during the study period were included in Study IV. Table 13 presents a 
comparison between the baseline characteristics before VA-ECMO (i.e. before cannulation) 
of survivors with those of non-survivors at 90 days after initiation of support. Survivors and 
non-survivors differed significantly in IHD prevalence, initial cardiac arrest rhythm, low-
flow duration, ROSC, median MAP, arterial pH and lactate just before cannulation. All 
cardiac arrests were witnessed by health care professionals on site with almost direct 
initiation of resuscitation, resulting in close to zero no-flow durations. Forty-six patients 
(64%) received VA-ECMO during ongoing CPR (absence of ROSC). The remaining 26 
patients (36%) were initially successfully resuscitated to sustained ROSC after median 10 
minutes (IQR: 2-17). Patients with sustained ROSC subsequently deteriorated secondary to 
refractory postarrest cardiogenic shock and VA-ECMO was initiated as the only remaining 
life-saving therapy. Sixty patients (83%) were cannulated by a femoral venoarterial (96%) 
or femoral artery-internal jugular vein access (4%). 
 
TABLE 13. Comparison of pre-VA-ECMO characteristics between survivors and non-survivors at 90 days 
after VA-ECMO initiation 
Pre-VA-ECMO   
characteristics  
MD 
(%) 
All patients 
(n = 72) 
Survivors  
(n = 31) 
Non-survivors  
(n = 41) 
P value 
Male gender 0 54 (75) 23 (43)  31 (57) 0.891 
Age (y) 0 56 (43-65; 11-76) 50 (36-62; 17-76) 59 (50-66; 11-76) 0.065 
≥65 (y) 0 16 (22) 5 (31) 11 (69) 0.280 
Weight (kg) 0 80 (73-90; 39-114) 78 (67-90; 51-102) 81 (75-90; 39-114) 0.308 
BMI (kg/m2) 0 25.9 (23.6-28.3) 24.7 (23.1-27.8) 26.6 (24.1-29.2) 0.098 
Clinical presentation      
Ischemic heart disease 0 47 (65) 16 (34) 31 (66) 0.034 
AMI 0 32 (44) 11 (34) 21 (66) 0.183 
STEMI 0 31 (43) 11 (35) 20 (65) 0.259 
Smoking 0 31 (43) 13 (42) 18 (58) 0.867 
Hypertension 0 30 (42) 12 (40) 18 (60) 0.658 
Valvular heart disease  0 24 (33) 10 (42) 14 (58) 0.866 
Dyslipidemia  0 18 (25) 5 (28) 13 (72) 0.131 
Diabetes mellitus 0 13 (18) 4 (31) 9 (69) 0.323 
Hypertrophic 
cardiomyopathy 
0 6 (8.3) 1 (17) 5 (83) 0.227 
Prior† myocardial 
infarction 
0 9 (13) 3 (33) 6 (67) 0.723 
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Atrial fibrillation 0 7 (9.7) 1 (14) 6 (86) 0.227 
Prior† PCI 0 7 (9.7) 2 (29) 5 (71) 0.691 
Prior† cardiac surgery  0 6 (8.3) 2 (33) 4 (67) 0.693 
Chronic renal failure 0 5 (6.9) 1 (20) 4 (80) 0.382 
Intoxication 0 5 (6.9) 4 (80) 1 (20) 0.158 
Primary graft failure after 
heart transplantation 
0 4 (5.6) 2 (50) 2 (50) 1.000 
Acute myocarditis 0 3 (9.7) 3 (100) 0 (0) 0.075 
Acute pulmonary embolus 0 3 (4.2) 1 (33) 2 (67) 1.000 
Endocarditis 0 3 (4.2) 2 (67) 1 (33) 0.574 
Cardiac arrest location      
Out-of-hospital  0 9 (12) 5 (56) 4 (44) - 
In-hospital  0 63 (88) 26 (41) 37 (59) 0.485 
Intensive care unit 0 22 (31) 9 (41) 13 (59) 0.807 
Catherization laboratory 0 18 (25) 6 (33)  12 (67) 0.336 
Ward 0 12 (17) 7 (58) 5 (42) 0.242 
Operating room 0 11 (15) 4 (36) 7 (64) 0.626 
Initial cardiac arrest 
rhythm  
     
Shockable rhythm  0 31 (43) 21 (68) 10 (32) - 
Non-shockable rhythm 0 41 (57) 10 (24) 31 (76) <0.001 
No-flow duration (min) 0 0 (0) 0 (0) 0 (0) - 
Low-flow duration (min) 0 21 (10-73; 1-197) 10 (2-45; 1-120) 32 (20-100; 1-197) <0.001 
ROSC  0 26 (36) 19 (73) 7 (27) - 
Time to ROSC (min) 0 10 (2-17; 1-48) 5 (2-10; 1-20) 20 (17-30; 15-48) <0.001 
Absence of ROSC* 0 46 (64) 12 (26) 34 (74) <0.001 
Time to cannulation 
(min)  
0 49 (20-107; 1-197) 55 (20-87; 1-120) 47 (20-116; 1-197) 0.670 
MAP (mmHg)‡ 0 50 (40-59) 55 (45-53) 45 (40-53) 0.001 
Arterial pH‡ 0 7.10 (6.94-7.30; 
6.55-7.57) 
7.18 (7.06-7.34; 
6.63-7.57) 
7.04 (6.90-7.22; 
6.55- 7.39) 
0.002 
Arterial lactate (mmol/L)‡ 0 12.0 (5.2-17.0;  
1.3-28.0) 
8.0 (2.9-12.9;  
1.3-20.0) 
15.0 (10.6-19.0; 
1.6-28.0) 
<0.001 
<10 (mmol/L) 0 28 (39) 19 (68) 9 (32) - 
10-20 (mmol/L) 0 36 (50) 12 (33) 24 (67) - 
>20 (mmol/L) 0 8 (11) 0 (0) 8 (100) 0.001 
<17 (mmol/L) 0 51 (71) 28 (55) 23 (45) - 
≥17 (mmol/L) 0 21 (29) 3 (14) 18 (86) 0.002 
Hemoglobin (g/L)‡ 0 109 (90-131) 114 (90-131) 108 (90-128) 0.785 
INR 6.9 1.3 (1.1-1.6) 1.3 (1.1-1.6) 1.4 (1.1-1.7) 0.589 
Creatinine (µmol/L)  2.8 130 (96-170) 133 (81-179) 124 (108-167) 0.887 
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GFR MDRD 
(mL/min/1.73m2) 
2.8 50 (38-71) 49 (40-77) 53 (35-66) 0.943 
ALT (µkat/L) 14 2.13 (0.91-6.92) 1.71 (0.91-5.50) 2.53 (0.97-12.59) 0.401 
Pre-VA-ECMO 
interventions 
     
Acute coronary 
angiography 
0 42 (58) 16 (38) 26 (62) 0.315 
Acute PCI 0 28 (39) 11 (39) 17 (61) 0.606 
Cardiac surgery  0 31 (43) 12 (39) 19 (61) 0.571 
Hemodialysis  0 9 (13) 3 (33) 6 (67) 0.723 
No. of inotropes and 
vasopressors‡§ 
0 2 (2-3) 2 (1-3) 3 (2-3) 0.073 
Intra-aortic balloon 
pump 
0 8 (11) 3 (37) 5 (63) 1.000 
Retrieval from external 
hospital 
0 29 (40) 14 (48) 15 (52) 0.463 
VA-ECMO insertion 
period¶  
     
2011-2015  0 36 (50) 15 (42) 21 (58) - 
2006-2010  0 36 (50) 16 (44) 20 (56) 0.812 
Bold indicates statistical significance. Categorical variables are presented as numbers (n) and percentages (%), and compared 
with the Chi-square, Likelihood ratio or Fischer’s exact test. Continuous variables are presented as median (interquartile range 
(IQR); range) and compared with the Mann-Whitney U test. ALT, alanine aminotransferase; AMI, acute myocardial infarction; 
BMI, body mass index; GFR MDRD, glomerular filtration rate modification of diet in renal disease; INR, international 
normalized ratio; MAP, mean arterial pressure; MD, missing data; PCI, percutaneous coronary intervention; ROSC, return of 
spontaneous circulation; STEMI, ST-elevation myocardial infarction; VA-ECMO, venoarterial extracorporeal membrane 
oxygenation. †Prior to current medical event/admission. *Continuous chest compressions at cannulation. ‡Just before 
cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan. ¶Postimplant 
variable only for descriptive purposes. 
 
The following variables were found to be significantly associated with 90-day mortality in the 
univariable logistic regression analysis: IHD, initial non-shockable rhythm, absence of ROSC, 
low-flow duration, MAP, arterial pH and lactate (Table 14A).  
 
TABLE 14A. Factors associated with mortality at 90 days after VA-ECMO initiation 
  Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
Male gender 0 1.08 0.37-3.16 0.891 - - - 
Age (y) 0 1.03 1.00-1.06 0.079 - - - 
≥65 vs. <65 (y) 0 1.91 0.59-6.21 0.284 - - - 
Weight (kg) 0 1.02 0.98-1.05 0.364 - - - 
BMI (kg/m2) 0 1.13 0.98-1.30 0.107 - - - 
Clinical presentation        
Ischemic heart disease 0 2.91 1.07-7.92 0.037 7.39 1.57-34.7 0.011 
AMI 0 1.91 0.73-4.97 0.186 - - - 
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Smoking 0 1.08 0.42-2.78 0.867 - - - 
Hypertension 0 1.24 0.48-3.20 0.658 - - - 
Valvular heart disease  0 1.09 0.40-2.94 0.866 - - - 
Dyslipidemia  0 2.41 0.76-7.71 0.137 - - - 
Diabetes mellitus 0 1.90 0.53-6.86 0.328 - - - 
Prior† myocardial 
infarction 
0 1.60 0.37-6.98 0.532 - - - 
Atrial fibrillation 0 5.14 0.59-45.2 0.140 - - - 
Prior† PCI 0 2.01 0.36-11.2 0.423 - - - 
Prior†cardiac surgery 0 1.57 0.27-9.16 0.618 - - - 
Chronic renal failure 0 3.24 0.34-30.6 0.304 - - - 
Intoxication 0 0.17 0.02-1.59 0.120 - - - 
Primary graft failure after 
heart transplantation 
0 0.74 0.10-5.59 0.774 - - - 
Acute myocarditis 0 0.36 0.03-4.19 0.416 - - - 
Acute pulmonary embolus 0 1.54 0.13-17.8 0.730 - - - 
Endocarditis 0 0.36 0.03-4.19 0.416 - - - 
Cardiac arrest location        
In-hospital  0 1.78 0.44-7.27 0.422 - - - 
Catherization laboratory 0 1.72 0.57-5.27 0.339 - - - 
Operating room 0 1.39 0.37-5.25 0.627 - - - 
Intensive care unit 0 1.14 0.41-3.14 0.807 - - - 
Ward 0 0.48 0.14-1.68 0.248 - - - 
Out-of-hospital  0 0.56 0.14-2.30 0.422 - - - 
Initial cardiac rhythm        
Shockable rhythm 0 0.15 0.05-0.43 <0.001 - - - 
Non-shockable rhythm 0 6.51 2.31-18.7 <0.001 12.2 2.83-52.7 0.001 
Absence of ROSC* 0 7.69 2.59-22.8 <0.001 2.46 0.51-11.9 0.262 
Low-flow duration (min) 0 1.02 1.01-1.03 0.008 1.01 0.99-1.03 0.398 
MAP (mmHg)‡ 0 0.92 0.88-0.97 0.002 - - - 
Arterial pH‡ 0 0.03 0.00-0.31 0.004 - - - 
Arterial lactate (mmol/L)‡ 0 1.17 1.07-1.27 <0.001 1.15 1.01-1.31 0.041 
Hemoglobin (g/L)‡ 0 1.00 0.98-1.02 0.983 - - - 
INR 6.9 1.00 0.53-1.90 1.000 - - - 
Creatinine (µmol/L)  2.8 1.00 0.99-1.01 0.693 - - - 
GFR MDRD 
(mL/min/1.73m2) 
2.8 1.00 0.99-1.01 1.000 - - - 
ALT (µkat/L) 14 1.02 0.98-1.01 0.373 - - - 
Pre-VA-ECMO 
interventions 
       
Acute coronary 
angiography 
0 1.63 0.63-4.20 0.316 - - - 
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Acute PCI 0 1.29 0.49-3.37 0.607 - - - 
Cardiac surgery 0 1.34 0.53-3.53 0.518 - - - 
Hemodialysis 0 1.60 0.37-6.98 0.532 - - - 
Intra-aortic balloon 
pump 
0 1.30 0.29-5.89 0.737 - - - 
No. of inotropes and 
vasopressors‡§ 
0 1.52 0.93-2.50 0.098 - - - 
Retrieval from external 
hospital 
0 0.70 0.27-1.81 0.463 - - - 
Bold indicates statistical significance. ALT, alanine aminotransferase; AMI, acute myocardial infarction, BMI, body mass 
index; CI, confidence interval; GFR MDRD, glomerular filtration rate modification of diet in renal disease; INR, 
international normalized ratio; MAP, mean arterial pressure; MD, missing data; OR, odds ratio; PCI, percutaneous 
coronary intervention; ROSC, return of spontaneous circulation; STEMI, ST-elevation myocardial infarction; VA-ECMO, 
venoarterial extracorporeal membrane oxygenation.†Prior to current medical event/admission. *Continuous chest 
compressions at cannulation. ‡Just before cannulation. §Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, 
milrinone, levosimendan. 
 
MAP and pH were excluded from the model due to high collinearity with lactate. pH but not 
lactate was excluded as the latter variable can be considered a more robust variable and less 
sensitive to administration of buffer solutions during CPR and the influence of PaCO2. Non-
linearity did not impact the logistic regression analysis according to the restricted cubic 
splines analysis, supporting the use of the model.  
 
Three independent factors made significant contributions to the model in the multivariable 
logistic regression analysis (Table 14B). Non-shockable rhythm as initial presenting cardiac 
arrest rhythm was the most significant predictor followed by presence of IHD and arterial 
lactate level.  
 
TABLE 14B. Factors associated with mortality at 90 days after VA-ECMO initiation 
  Univariable logistic regression Multivariable logistic regression 
Variables MD (%) OR 95% CI P value OR 95% CI P value 
Ischemic heart disease 0 2.91 1.07-7.92 0.037 7.39 1.57-34.7 0.011 
Non-shockable rhythm  0 6.51 2.31-18.7 <0.001 12.2 2.83-52.7 0.001 
Absence of ROSC*‡ 0 7.69 2.59-22.8 <0.001 2.46 0.51-11.9 0.262 
Low-flow duration (min) 0 1.02 1.01-1.03 0.008 1.01 0.99-1.03 0.398 
MAP (mmHg)‡ 0 0.92 0.88-0.97 0.002 - - - 
Arterial pH‡ 0 0.03 0.00-0.31 0.004 - - - 
Arterial lactate (mmol/L)‡ 0 1.17 1.07-1.27 <0.001 1.15 1.01-1.31 0.041 
Bold indicates statistical significance. CI, confidence interval; MAP, mean arterial pressure; MD, missing data; MAP, mean 
arterial pressure; MD, missing data; OR, odds ratio; ROSC, return of spontaneous circulation; VA-ECMO, venoarterial 
extracorporeal membrane oxygenation. *Continuous chest compressions at cannulation. ‡Just before cannulation. 
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The full model with the independent predictors, was statistical significant, χ2 (df = 5, n = 72) 
= 41.765; p <0.001. Thus, the model was able to discriminate between survivors and non-
survivors at 90-days. The χ2 for Hosmer-Lemeshow’s Test was 7.619 with a significance 
level of p = 0.47, which further supports the use of our model. The model as a whole 
explained between 44% (Cox and Snell R2) and 59% (Nagelkerke R2) of the variance of the 
90-day mortality and overall correctly classified 83% of the cases. The sensitivity and 
specificity of the model was 85% and 81%, respectively, giving a positive predictive value 
of 85% and a negative predictive value of 81%.  
 
The Kaplan-Meier survival curves until 90 days after VA-ECMO initiation are presented in 
Figure 10 and indicate significant worse outcome for (A) lactate level ≥17mmol/L 
(153mg/dL) (90% specificity), and (B) non-shockable compared with shockable rhythm. All 
patients (8 of 8) with a lactate level >20mmol (180mg/dL) died within 6 days.  
 
 
FIGURE 10. Kaplan-Meier survival curves until 90 days after initiation of VA-ECMO support related to (A) 
arterial lactate intervals at initiation of VA-ECMO, and (B) initial cardiac arrest rhythm, with 95% confidence 
intervals, in 72 patients with cardiac arrest. VA-ECMO, venoarterial extracorporeal membrane oxygenation. 
 
The all-cause mortality at 90 days, which was the primary endpoint, was 57% (n = 41). 
Within 72 hours 19 patients (26%) died and within the first week after VA-ECMO onset 28 
patients (39%) succumbed. During VA-ECMO 38 patients (53%) died. The in-hospital 
mortality was 57% (n = 41) and 43% (n = 31) were discharged home, all with a good 
neurological outcome defined as CPC score 1-2 as presented in Table 15. The main causes 
of death during VA-ECMO were brain injuries and multiorgan failure, 21% (n=15) 
respectively, and within 90 days anoxic brain injury 22% (n=16) (Table 15).  
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TABLE 15. Outcomes 
Variables MD  
(%) 
All patients  
(n = 72) 
VA-ECMO duration (days) 0 5 (2-12; 1-55) 
VA-ECMO destination 
  
Death during VA-ECMO 0 38 (53) 
Successful weaning* 0 31 (43) 
VA-ECMO to heart transplantation   0 3 (4.2) 
VA-ECMO to LVAD  0 0 (0) 
Mortality within   
24 hours 0 13 (18) 
48 hours 0 17 (24) 
72 hours 0 19 (26) 
7 days  0 28 (39) 
30 days 0 38 (53) 
90-day mortality  0 41 (57) 
In-hospital mortality 0 41 (57) 
Discharge to home  0 31 (43) 
Days from VA-ECMO initiation to discharge home 0 51 (29-101; 13-295) 
CPC score at discharge to home 0 31 (43) 
CPC 1-2 0 31 (100) 
CPC 3-4 0 0 (0) 
Cause of death during VA-ECMO  0 38 (53) 
Cerebral† 0 15 (21) 
Multiorgan failure 0 15 (21) 
Cardiac‡ 0 4 (5.5) 
Bleeding§ 0 3 (4.2) 
Miscellaneous¶ 0 1 (1.4) 
Cause of death within 90 days 0 41 (57) 
Cerebral† 0 16 (22) 
Multiorgan failure 0 15 (21) 
Cardiac‡ 0 4 (5.5) 
Bleeding§ 0 3 (4.2) 
Miscellaneous¶¥ 0 3 (4.2) 
Categorical and continuous variables are presented as numbers (n), percentages (%), and median (interquartile range (IQR); 
range), respectively. CPC, cerebral performance category; LVAD, left ventricular assist device; MD, missing data; VA-ECMO, 
venoarterial extracorporeal membrane oxygenation. *Survival >48 hours after weaning/without re-initiation of VA-ECMO. 
†Fatal anoxia, brain death, stroke. ‡Sudden cardiac arrest, myocardial infarction, heart failure. §Lung, gastrointestinal, 
retroperitoneal. ¶Iatrogenic air entry into VA-ECMO-circuit (n = 1). ¥Pulmonary embolus and ischemic colitis (n = 1), 
pulmonary embolus (n = 1).  
 
 
 
 47 
 
Figure 11 depicts the most frequent complications after initiation of VA-ECMO being renal 
failure necessitating hemodialysis (54%) followed by pneumonia (43%) and anoxic brain 
injuries (19%). 
 
 
FIGURE 11. Main complications after initiation of venoarterial extracorporeal membrane oxygenation in 72 
patients with cardiac arrest.  
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5 DISCUSSION 
The major findings in this thesis were as follows.  
In an unselected population with refractory cardiogenic shock three independent pre-VA-
ECMO predictors for 90-day mortality were identified; arterial lactate level, number of 
inotropes and vasopressors, and presence of IHD, which all demonstrated an explicit fall in 
survival during the first 20 days, after which they leveled out until 90 days after VA-ECMO 
initiation. The 90-day mortality rate corresponded to the in-hospital mortality rate both 
reaching 54% (Study I). 
In patients with refractory postcardiotomy cardiogenic shock two independent pre-VA-ECMO 
predictors for 90-day mortality in patients with refractory postcardiotomy cardiogenic shock; 
arterial lactate level and IHD.  Moreover, the 90-day morality rate was 57% and the in-hospital 
mortality rates was 56%. The presented in-hospital mortality rate was one of the lowest rates 
reported in unselected refractory postcardiotomy patients (Study II).  
In an unselected non-surgical population with refractory cardiogenic shock supported by VA-
ECMO two independent pre-VA-ECMO predictors for 90-day mortality were identified; 
arterial lactate and number of vasopressors and inotropes just before cannulation (Study III). 
In an unselected population with cardiac arrest prior to VA-ECMO three independent 
predictors for mortality were identified; initial non-shockable rhythm, presence of IHD, and 
arterial lactate, as independent pre-VA-ECMO predictors for 90-day mortality in patients with 
cardiac arrest prior to VA-ECMO, whereas low-flow duration, ROSC and age were not 
significant (Study IV).  
 
5.1 PRIMARY ENDPOINT  
The primary endpoint mortality within 90-days after initiation of VA-ECMO was chosen 
throughout the thesis over 30-day mortality, as in Study I 7.2% (13 of 181 patients), Study II 
6.7% (7 of 105 patients), Study III 7.9% (6 of 76 patients) and Study IV 5.6% (4 of 72 
patients) of patients had VA-ECMO support ≥30 days (up to 55 days). Furthermore, the 
Kaplan-Meier survival curves flattened out before reaching 90 days, which indicated that it 
would be of limited additional value to extend to follow-up beyond 90 days regarding 
identification of pre-implant outcome predictors. In addition, the outcome variable 90-day 
mortality was used as the also commonly used alternative, alive at hospital discharge, does not 
 49 
 
include a specific time span. Even though patients may survive 90 days after VA-ECMO 
implantation, individual patients may still be hospitalized. Therefore, the variable discharge to 
home in was added as exemplified by the fact that 13% of patients (23 of 181) had a longer 
hospital stay than 90 days (up to 295 days). 
Cause of death after discharge was not chosen as an outcome variable in the thesis as it is 
dependent on follow up time, patient age, life style and comorbidity with different life 
expectancy. As follow up time increases other factors independent of etiology for VA-ECMO 
support will become more important as cause of mortality. Studies within the field have 
therefore, besides alive at hospital discharge, focused on specific time intervals after VA-
ECMO initiation preferably reporting 30-, 90-day, 1-year mortality vs. survival rates rather 
than an unspecific time point for outcome as “after discharge” which therefore is not presented 
in Study I-IV.  
 
5.2 OUTCOME PREDICTORS 
This thesis identified pre-VA-ECMO predictors for 90-day mortality in an undifferentiated 
population of refractory cardiogenic shock patients (Study I), as well as in specific subgroups 
defined in Study II-IV.   
5.2.1 Arterial lactate  
Lactate is a metabolic end product of anaerobic glycolysis and is considered to be indicator of 
tissue perfusion, which is affected by both macro- and microcirculation. The worse the tissue 
hypoperfusion is the higher the lactate and risk for mortality.46, 70-73 In refractory cardiogenic 
shock the arterial lactate level is a marker of general tissue hypoperfusion, following low 
cardiac output with impaired tissue oxygenation and anaerobe metabolism.72, 73 Regarding 
physiology and lactate behavior, cardiogenic shock with tissue hypoperfusion, has several 
pathophysiological consequences including imbalance between oxygen delivery and 
consumption, global tissue hypoxia, and anaerobic metabolism under the simultaneous 
influence of catecholamines. The resulting behavior of lactate, including its clearance, as being 
the provider of “rescue energy” is a complex topic and was not the aim of this thesis. However, 
lactate physiology in critical illness including cardiogenic shock and after cardiac surgery has 
been described in detail elsewhere.70, 74-80 Metabolic acidosis will be treated with intravenous 
buffer solutions, including sodium bicarbonate, which will influence base excess and arterial 
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pH but not arterial lactate. Thus, in Study I-IV arterial lactate levels was focused upon and 
not base excess levels.  
The importance of arterial lactate in the setting of cardiogenic shock and indication for VA-
ECMO support has been previously discussed by other groups. With a similar study population 
size, 179 compared to 181 patients in Study I, Truby et al.,39 only found etiology of refractory 
cardiogenic shock as a significant pre-VA-ECMO predictor for in-hospital mortality (61%). 
However, several of their variables had a large proportion of missing data, including arterial 
lactate (34%). Remarkably, the median arterial lactate level in their study cohort was 5.45 
mg/dL (IQR: 2.7-9.3) corresponding to 0.6 mmol/L (IQR: 0.3-1.0), which should be compared 
with a median of 7.1 mmol/L (IQR: 3.1-14.0) in Study I (Table 3). Most likely, this is 
explained by a selection bias, where arterial lactate sampling was collected from only relatively 
stable patients and not from patients rapidly deteriorating due to refractory cardiogenic shock 
with a more pronounced oxygen delivery deficit. This illustrates the weakness of studies with 
incomplete data, where a high proportion of missing data not missing at random may lead to 
internally and externally unreliable results. In contrast, all variables included in the 
multivariable logistic regression analysis were complete and thus arterial lactate, a marker of 
severe hypoperfusion, became a highly significant independent predictor of 90-day mortality 
(Table 4A, B). Arterial lactate has in agreement with Study I also been found to be an 
independent pre-VA-ECMO predictor of short and midterm survival in several other single 
center studies with unselected patients’ populations.40, 42, 43, 64, 67, 81 In Study I-IV, it was 
possible to identify specific lactate intervals where increasing levels of lactate indicated worse 
survival as presented in the Kaplan-Mayer survival curves (Figure 3A, 5A, 8, 10A). 
In Study II, evaluating refractory postcardiotomy cardiogenic shock patients, lactate was 
identified to have an OR of 1.22 per mmol/L, again implying progressively worse outcomes 
with increasing lactate levels. High lactate levels at the end of cardiac surgery due to an 
imbalance between oxygen delivery and requirement resulting in tissue hypoxia and organ 
failure has previously been identified as an independent predictor of negative outcome after 
cardiac surgery.76, 78, 80 Regarding the lactate cut off level of 10 in Study II (Figure 5A) and 
the survival ROC, a clear postoperative cut-off value for lactate has previously not been 
identified and values consequently differ between studies. A survival ROC analysis of lactate 
identified a value of 5.8mmol/L, corresponding to a sensitivity of 75.0% and specificity of 
40.0%. However, despite this value being statistically correct it is not a clinically relevant “cut 
off” value to be applied in an VA-ECMO practice, where the likelihood of death in the absence 
of VA-ECMO is deemed to be extremely high i.e. a significant part of patients will also die 
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with lower lactate levels. Instead, lactate was identified as an independent predictor for 90-day 
mortality with an OR of 1.22 per mmol/L, implying progressively worse outcomes with 
increasing lactate levels. Based on our daily practice we divided the study population into four 
chosen subgroups of lactate with arbitrary cut off levels of <5, 5-9.9, 10-14.9, ≥15mmol/L 
(Table 7) to facilitate clinical interpretation of lactate as a strong and significant predictor. 
However, postulating cut off levels whether statistically calculated or arbitrary chosen entail a 
risk that these cut off levels will be clinically perceived as cut off levels to either offer or to 
exclude patients from VA-ECMO support. This is part of a larger discussion, which was not 
the aim of this thesis to elucidate. However, in such a discussion the concept of optimization 
of sensitivity and specificity according to ROC analysis has to be addressed. There is an 
obvious risk to overemphasize the importance of a high sensitivity to identify patients (the true 
positives) who died in this setting. Increasing sensitivity will lower the lactate cut off to very 
low levels, as also patients died with normal lactate levels.  Consequently, a significant part of 
the patients with high lactate levels also survived. Therefore, in accordance to other clinical 
centers, specificity can be considered to be more important to focus upon when to facilitate 
clinical interpretation of lactate on outcome. Thus, it is more important to identify patients who 
will not die (the true negatives). Besides dividing the study population into the four above 
mentioned lactate groups to facilitate interpretation of the importance on the increasing levels 
of lactate on outcome, it was additionally chosen to present a more simplified and clinically 
applicable figure (Figure 5A) with 10 as an arbitrary cut off level, as a single cut off level is 
easier to refer to than four different cut off subgroups. The cut off level of 10 was chosen as it 
corresponds to a specificity of 91% (ROC survival of 9%) implying that at a lactate level of 
10 identified >90% of the patients that died in the population. To rise the cut off to 15mmol/L 
would have identified 100% of non-survivors and at the same time raised the question if VA-
ECMO out of ethical reasons should be offered to patients with near to or 100% expected 
mortality (same single cut off approach was chosen in Study IV, Table 10A). 
Moreover, the identification of arterial lactate as an independent pre-VA-ECMO predictor of 
mortality after cardiac surgery complies with the two studies of Park et al.46, 71 on 115 and 93 
patients, respectively, where blood lactate before initiation of VA-ECMO) was as an 
independent predictor of in-hospital mortality (OR: per unit lactate, 1.19 and 1.13, 
respectively).  Likewise, Papadopoulos et al.45 discovered that a pre-VA-ECMO serum lactate 
level of >120mg/dL (>13.3mmol/L) significantly worsened in-hospital survival in 360 
postcardiotomy cardiogenic shock patients (OR: 2.6) as did Rastan et al.,44 who identified that 
a lactate level of >4mmol/L in the operating room, and >10 mmol/L immediately after VA-
ECMO initiation in 517 refractory postcardiotomy cardiogenic shock patients, were significant 
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predictors of in-hospital mortality (OR: 2.21 and 2.65, respectively). Additionally, an 
important feature that strengthens the impact of arterial lactate as a predictor was that we in 
Study II identified that increasing intervals of arterial lactate corresponded with progressively 
worse survival (Table 7 and Figure 5A), which to our knowledge is the first time to be 
reported in refractory postcardiotomy cardiogenic shock in a pre-VA-ECMO setting. 
Arterial lactate remained an independent pre-VA-ECMO predictor of 90-day mortality in 
Study III (Table 11A, B), evaluating non-surgical refractory cardiogenic shock, which is 
agreement with several other studies with selected or unselected non-surgical populations.40, 
61, 67   
Finally, in Study IV, lactate level was also found to be predictive of 90-day mortality in the 
pre-VA-ECMO cardiac arrest setting, which is only supported by a limited number of 
previous cardiac arrest studies,82-86 presumably explained by missing lactate data in the 
majority of these studies. In conventional CPR, lactate levels have previously been 
identified as a survival and neurological prognostic marker.87 In cardiac arrest or refractory 
postarrest cardiogenic shock, arterial lactate is as previously discussed indicative of the 
magnitude of anaerobic metabolism following systemic hypoperfusion and tissue hypoxia 
and consequently epitomizes a surrogate marker of “no and low-flow duration” with 
insufficient tissue perfusion resulting in end-organ failure.87-90  In Study IV, a lactate cut 
off level of ≥17mmol/L was identified (Table 13 and Figure 10A) to correspond with a 
specificity of 90% (10% ROC survival), in accordance to the previous considerations on 
specificity and sensitivity discussed above. A lactate cut off level of 20mmol/L would have 
identified 100% of non-survivors and at the same time raised the question if VA-ECMO 
out of ethical reasons should be offered to patients with a near to or 100% expected 
mortality. Using the 20mmol/L criterion, 8 of 72 patients (11%) in Study IV should not 
have been cannulated. Similarly, Megarbane et al.91 in a study including 66 extracorporeal 
CPR (ECPR) patients found that a pre-VA-ECMO lactate level ≥21mmol/L was associated 
with 100% mortality. However, it must be kept in mind that lactate levels can reach 
extreme values before cannulation and still be associated with survival in poisoning-related 
refractory cardiac arrest.92 
5.2.2 Inotropes and vasopressors 
Administration of intravenous inotropes and vasopressors,20, 93 often in combination, is the 
pharmacological approach to initially counteract refractory cardiogenic shock.  Intravenous 
inotropes and vasopressors have in this context been identified to be a significant independent 
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predictor of 90-day mortality, which is supported by previous studies indicating that the extent 
of vasoactive support predicts outcome in various ECMO and non-ECMO settings.45, 53, 94-96  
The amount of intravenous inotropic and vasopressor support was in Study I-IV graded into 
the simple and clinically relevant “number” of ongoing drugs just before cannulation for VA-
ECMO. The time (number infusion hours) or mean drug doses of vasoactive agents before 
VA-ECMO was deliberately not studied, though previously described,94, 97 being a challenging 
variable to interpret and even more complex when the aim is to facilitate a clinically applicable 
and rapid approach to predict risk were pharmacological support is included. A number-of-
hours-analysis would also have to address interchanging doses and combinations of drugs with 
separate pharmacokinetics. This would involve different number of hours per drug in 
combination with the simultaneously ongoing volume loading in patients, who are often 
rapidly deteriorating hemodynamically within the last hours before cannulation. Moreover, to 
calculate the mean doses of the specific drugs during an arbitrary number of pre-VA-ECMO 
hours is challenging as patients with refractory cardiogenic shock are on a slippery sliding 
slope, which will misallocate interpretation of mean doses in relation to time of cannulation as 
initially lower upstart doses with fewer drugs several hours or days earlier will mask higher 
doses closer to cannulation. To overcome the complicated calculation and interpretation of the 
impact of pharmacological support on outcome, we applied a simpler and clinically more 
applicable method to facilitate evaluation and risk prediction by counting the number of drugs, 
which were considered to have a pharmacological effect in the patient last before cannulation 
regardless of overall mean dose or number of hours.  
One may argue that behind use of escalating doses of vasoactive drugs and increasing lactate 
levels is a decrease in the cardiac output. Therefore, adequate hemodynamic assessment 
including cardiac output/ index values before initiation of VA-ECMO in the two groups 
(survivors/ non-survivors) could be considered to determine if this is true. Furthermore, in the 
absence of such a measurement, the use of vasoactive drugs could have led to more tissue 
ischemia and increasing lactate levels. However, monitoring cardiac output/cardiac index 
(CO/CI) before initiation of VA-ECMO was not the primarily applicable diagnostic approach 
in our setting with an undifferentiated refractory cardiogenic shock population threatened with 
impending death, where 49% (51 of 105) of the patients undergoing cardiac surgery (Study 
II) were not able to be separated from perioperative CPB, and thus accordingly were 
cannulated in the OR (Table 7 and 8A). Furthermore, in Study I, 40% of the patients 
underwent CPR within 12 hours before cannulation, 25% (46 of 181) under ongoing heart 
compressions, and 7% and 35% of the patients were cannulated in the catheter laboratory and 
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or retrieved from external hospitals general intensive care units (often without specific CO/CI 
monitoring), respectively. Evidently, the majority of our patients were not slowly deteriorating 
after or during a complete hemodynamic investigation or monitoring, but rapidly deteriorating. 
Insertion of a complimentary pulmonary artery catheter for measuring of CO/CI beyond the 
rapid information given by echocardiography, the patient’s clinical and metabolic state, and 
the level of other ongoing support, were not considered being sufficiently valuable in bringing 
further information crucial on deciding on the suitability of cannulation. More so, this would 
have risked delaying implantation of VA-ECMO in these extremely hemodynamically 
unstable and critically ill patients. Consequently, CO/CI was only registered in 24% of the 
patients before initiation of VA-ECMO.  
To our knowledge, Study I and III are the first studies to present that the number of inotropes 
and vasopressors at initiation of VA-ECMO independently predicts survival at 90-days in 
adults with refractory cardiogenic shock. 
5.2.3 Ischemic heart disease 
In Study I and II, IHD, was the only organ specific predictor. This is supported by previous 
studies where IHD in general is associated with worse outcomes compared with non-IHD.2, 98  
Evidently, all patients in Study II who underwent elective CABG had IHD. These two factors 
were significant in the multivariable analysis, but highly correlated in the multicollinearity 
analysis. Furthermore, not all patients with IHD underwent CABG unless presence of 
significant and graftable stenosis, whereby IHD had a higher prevalence than CABG. Thus, 
IHD was kept and CABG excluded from the model. Moreover, IHD correlated significantly 
with AMI, wherefore AMI also was removed from the model.  
In the non-surgical VA-ECMO population (Study III) neither AMI, IHD or other non- 
surgical etiologies were identified as independent predictors of 90-day mortality. Despite AMI 
being the most frequent reason for CS in other studies, 3, 4, 99 we were not able to identify 
AMI per se as an independent predictor of 90-day mortality in with refractory cardiogenic 
shock, even though cardiovascular disease generally is associated with worse expected 
outcome. 63, 98 It must therefore be recognized that neither AMI per se nor the cohort of other 
non-surgical etiologies were significantly associated with mortality after initiation of VA-
ECMO, which agrees with the recently published single center study by Waha et al. 32 Thus, 
the severity of cardiogenic shock indicated as the levels of lactate and number of vasoactive 
agents discussed above just before start of VA-ECMO may be more predictive of outcome 
than the specific etiology of cardiogenic shock. 
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The significance of IHD as a pre-implant predictor of 90-day mortality after VA-ECMO 
initiation was further verified by its identification in Study IV. This finding is supported by 
previous studies indicating poor outcome in patients with IHD undergoing cardiac arrest and 
that sudden cardiac death, being the worldwide leading cause of all deaths, occurs in the 
majority in patients with atherosclerotic coronary artery disease (65–85%).100, 101  
5.2.4 Non-shockable rhythm 
There are no universal time criteria to define refractory cardiac arrest. Most studies have 
arbitrary excluded patients with low-flow durations (i.e. CPR duration) below 10-30 minutes. 
In contrast, we included patients with low-flow durations down to 1 minute (median 21 
minutes, IQR: 10-73), to evaluate the influence of the time component low-flow duration on 
outcome. This permitted us to analyze the complete range of low-flow durations with other 
factors, including lactate, without excluding patients with arbitrary short low-flow durations. 
The finding in Study IV that initial non-shockable rhythm was an independent predictor of 
mortality after VA-ECMO initiation (Table 14A, B) is in agreement with several other 
studies.9, 84, 102-106 Conversely, Dennis et al.85 failed to find such an association, most 
probably due to a type II error with only 3 out of 37 included patients with asystole (i.e. 
non-shockable rhythm).  
Indeed, in the univariable logistic regression analysis low-flow duration and absence of ROSC 
were identified as significant predictors for 90-day mortality after VA-ECMO initiation. 
However, both factors lost their significance in the multivariable analysis (p = 0.398 and p = 
0.262, respectively) in contrast to the factors non-shockable rhythm, lactate and IHD. Several 
studies have reported low-flow duration to be an independent predictor of outcome,102-104, 107, 
108 but in contrast to Study IV, those studies did not include lactate in the analyses. This may 
further support that arterial lactate represent a metabolic marker superior to the precarious 
factor low-flow duration, which is influenced by CPR quality, the often-inexact no and low-
flow time estimations, and the possibility of undetected interim periods of ROSC during 
ongoing CPR. Thus, the metabolic state, expressed as level of lactate just before start of VA-
ECMO, seems to be more predictive of outcome than low-flow time (i.e. CPR duration) or 
absence of ROSC. The latter further supports that lactate should be obtained from patients 
during and after CPR when VA-ECMO is considered as salvage therapy.  
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5.3 SELECTION OF VA-ECMO CANDIDATES 
VA-ECMO for refractory cardiogenic shock is a highly resource demanding therapy with 
potential life-threatening complications. Additionally, even if VA-ECMO support is instituted 
as salvage therapy for refractory cardiogenic shock, mortality remains high. Therefore, optimal 
selection of suitable candidates and timing of implantation are crucial. Consequently, it is 
important to identify independent pre-VA-ECMO predictors on mortality without 
simultaneously including on-VA-ECMO variables in the outcome analysis. Only a limited 
number of studies have specifically addressed pre-VA-ECMO factors for risk prediction in an 
undifferentiated population with refractory cardiogenic shock.14, 39, 64 In addition, earlier larger 
studies have often reported a combination of non-surgical and surgical patients,14, 35, 39, 53, 63, 64 
not presented rate of missing or considerably incomplete data,14, 32, 33, 40, 61, 66 or as discussed 
above, included both variables before and during VA-ECMO.65, 66 
The multicenter study by Schmidt et al.,14 including 3846 patients with refractory cardiogenic 
shock receiving VA-ECMO from 280 centers (patients who received VA-ECMO during CPR 
were excluded from their analysis) demonstrated a hospital mortality rate of 58%, compared 
with 54% in Study I, which included patients receiving VA-ECMO during CPR. Schmidt et 
al.14 identified 11 factors, including age, weight, chronic renal failure, time on mechanical 
ventilation before initiation of VA-ECMO, extra-cardiac organ failures, cardiac arrest, 
congenital heart disease, cause of cardiogenic shock, hemodynamic state, serum bicarbonate 
value, and peak inspiratory pressure, to be pre-VA-ECMO predictors of in-hospital mortality. 
However, in multicenter based registries the proportion of missing data has to be considered 
and in the study by Schmidt et al. only 23% of the patients had complete data.14 Moreover, a 
single center study like Study I avoided the inherent intercenter variability of practice habits, 
patient selection and data reporting, which results in heterogeneity when pooled analyses are 
performed. In contrast, almost all variables included in our analysis had complete data and no 
patients were lost during follow up.  
It must also be recognized that in Study I differing etiologies of refractory cardiogenic shock 
created three distinct subgroups of patients within our overall cohort, each having differing 
expected outcomes as described in previous studies.2, 14, 39, 81, 109, 110 However, Study I 
demonstrated that none of the three etiology cohorts significantly predicted 90-day mortality 
after initiation of VA-ECMO (Table 4A). Thus, the hemodynamic state during refractory 
cardiogenic shock, as indicated by lactate levels, level of pharmacological support and the 
presence of IHD, appeared to be more important than the specific cardiac etiology causing 
refractory cardiogenic shock. 
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Previous outcome studies in refractory postcardiotomy cardiogenic shock have also not 
addressed explicitly pre-VA-ECMO predictors for outcome, but rather combining 
preoperative, surgical, and on-VA-ECMO (i.e. during support) factors. However, inclusion of 
on-VA-ECMO factors (i.e. after cannulation) will evidently be problematic when the aim is to 
predict outcome before VA-ECMO is initiated (i.e. just before cannulation). In addition, to 
focus on exclusively pre- and intraoperative variables may only be appropriate in patients who 
cannot be weaned from CPB, i.e. bridged directly from CPB to VA-ECMO, as 11-65% of 
studied postcardiotomy cardiogenic shock patients were weaned from CPB and transported to 
the ICU before VA-ECMO initiation due to hemodynamic deterioration after a varying 
number of hours or days.2, 8, 34, 44, 46, 49, 51  
Rastan et al.44 included 517 patients with refractory postcardiotomy cardiogenic shock in the 
largest published single center study. Many preoperative, surgical, and on-VA-ECMO factors 
were included in the analysis, whereby several independent predictors for in-hospital mortality 
were identified. Merely, 40% of the patients were bridged directly to VA-ECMO from CPB. 
However, in patients weaned from CPB, factors that occurred between weaning from CPB and 
start of VA-ECMO were not included in the analysis by Rastan et al.44 This approach omits 
the identification of particularly pre-VA-ECMO predictors in the majority (60%) of patients. 
Equally, Papadopoulos et al.45 included 360 postcardiotomy cardiogenic shock patients in the 
second largest single center study in which 7 independent predictors for in-hospital mortality 
were identified, while type of cannulation, an on-VA-ECMO risk factor, was included in the 
risk factor analysis. In contrast, in Study II we included several complementary variables after 
surgery until start of VA-ECMO in the analysis in addition to preoperative and surgical factors. 
To our knowledge, Study II is the first study to specifically address identification of pre-VA-
ECMO predictors for 90-day mortality in unselected patients with refractory postcardiotomy 
cardiogenic shock.  
In Study II the in-hospital mortality rate was 56%, which to our knowledge is one of the lowest 
mortality rates in an undifferentiated cohort with refractory postcardiotomy cardiogenic shock 
population supported with VA-ECMO reported from a single center. In comparison, in-
hospital mortality rates have been reported to be between 53.4 and 76.3% in earlier studies.2, 
44, 45, 53 The incidence of postcardiotomy VA-ECMO at our tertiary center was 1.3% of the 
patients undergoing cardiac surgery, which is in the midrange of other publications within the 
field (0.6-2.9%) and similar to the large publications by Doll et al., 1.2%2  and Rastan et al., 
1.3%.44 Nevertheless, outcomes in refractory postcardiotomy cardiogenic shock supported by 
VA-ECMO are overall poor, which emphasizes identification of clinically usable predictors 
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to optimize prognostication and thereby selection of suitable candidates, who are considered 
to have a reasonable chance of survival by initiation of VA-ECMO. 
In Study II 51% of the population was successfully weaned from VA-ECMO, in comparison 
to between 31% and 63.5% in earlier publications.2, 44, 45, 55 Nevertheless, comparisons between 
studies are demanding due to unclear definitions on what can be considered to be successful 
weaning, i.e. survival time after weaning, and non-reporting of data.8, 44 The percentage of 
patients discharged alive, without having been bridged to long term mechanical circulatory 
support (ventricular assist device [VAD]) heart transplantation, should be related to the 
reported percentage of successful weaning, regardless of having survived weaning with an 
arbitrary defined number of hours or days, besides comparing patient characteristics, weaning 
and bridging rates. 
To estimate the proportion of patients who were excluded from VA-ECMO at our tertiary 
center because they were too sick would be to subtract the 2.5% 30-day mortality rate in all 
our patients undergoing cardiac surgery (during the study period), with the 0.7% mortality rate 
in the patients supported with VA-ECMO (1.3% of all our patients received VA-ECMO, and 
51% of them died within 30 days: 1.3 x 0.51 = 0.7%). Thus, 2.5% - 0.7% = 1.8% of the patients 
were probably excluded from VA-ECMO because they were either too sick or died after 
discharge within 30 days after the operation. 
Besides Study III, Waha et. al.32 have published the large and only single center study that 
has focused on the impact of specifically pre-ECMO predictors of outcome in unselected 
patients with refractory cardiogenic shock receiving VA-ECMO without prior surgery. The 
study by Waha et. al. 32 had several similarities with Study III: the number of included 
patients’ n = 83 vs. n = 76: proportion of males 74% vs. 74%, PCI in AMI patients 93% vs. 
92%, pre-ECMO CPR 55% vs. 54%, VA-ECMO duration median 6 days vs. 5 days, and death 
during VA-ECMO 43% compared with 46% in Study III. 
The lower in-hospital and 18-month mortality, 50.0% and 51.3% respectively, in Study III, 
compared with the data presented by Waha et al., 68.7% and 81.9% respectively, may partly 
be explained by an older study population (median age 9 years higher, all 14 patients >75 years 
died prior to hospital discharge) and a higher rate of AMI (64% vs. 51% in Study III). An 
unexpected and uncommented finding by Waha et al. was a higher pre-VA-ECMO lactate in 
survivors compared with non-survivors, which is in blatant disparity to the results in Study 
III and earlier studies on VA-ECMO treatment of non-surgical refractory cardiogenic 
shock.35, 40, 61 This may possibly be explained by a selection bias, i.e. that arterial lactate 
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sampling was restricted to relatively circulatory stable patients and omitted in unstable 
refractory cardiogenic shock patients with a more manifest oxygen deficit (rate of missing data 
not presented). Thus, such a selection bias may be clarified by the non-random absence of 
complete data, where a significant proportion of missing data may lead to unreliable results. 
Conversely, all variables included in the multivariable logistic regression analysis of Study 
III were complete and thereby arterial lactate, an indicator of severe tissue hypoperfusion, was 
identified as a significant independent predictor of 90-day mortality.  
 
5.4 STATISTICAL CONSIDERATIONS 
5.4.1 Rational for use of logistic regression vs. Cox regression 
 
Death at 90 days is a time-to-event outcome just as 30-day mortality is as for example a 
surgical quality metric used to assess surgical quality and to enable comparison of surgical 
performances between centers. However, this thesis focused on the binary outcome dead or 
alive at a fixed time point (90 days) without considering the time-to-event component, and not 
when in time the event (death) happened until the time point 90 days had been reached i.e. it 
was not in the interest of this thesis to consider if the individual patient had died on day one or 
day eighty-five, but only if the patient was dead at 90 days (90-day mortality). For this reason, 
logistic regression was used, which is in accordance to the most cited articles within the field, 
especially within the surgical domain.2, 8, 44-49, 51, 53, 71, 80, 111 Furthermore, this facilitates 
comparison of data presented in Study I-IV with those seminal studies. Moreover, Cox 
regression relies on proportional hazards, which in the case of VA-ECMO patients is not 
fulfilled due to a much higher early than late mortality. Thus, logistic and not Cox regression 
was chosen through Study I-IV. 
5.4.2 Collinearity 
Looking at the initial model of Study II from a surgical point of view, it can be argued to keep 
AMI in the model as patients with AMI are empirically known to be associated with high risk 
of perioperative mortality and thereby being a factor always considered before accepting these 
patients for acute surgery. However, there was a lot of collinearity among variables which 
implied large overfitting and therefore impairing the predictive power of the model outside the 
sample analyzed. In fact, the high collinearity between AMI, CABG, and IHD, as they are 
likely to be the same thing (all patients receiving CABG obviously have IHD), in combination 
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with the limited number of events in Study II (too few survivors: AMI, n = 5; prior CABG, n 
= 2; prior PCI, n = 3; isolated CABG, n = 3 (Table 7) had to be addressed, in order to prevent 
that “insufficient” data would have resulted in an unstable multivariable model.112 
Furthermore, not all patients with IHD will be grafted unless presence of significant and 
graftable stenosis, whereby IHD has a higher prevalence than CABG and the removal of AMI 
further strengthens the classification of IHD. Thus, in order to improve the robustness of the 
model based on the arguments discussed, AMI and CABG were excluded from the final 
model. The same statistical considerations applied for pH and lactate, the latter being a more 
robust variable less sensitive to influence by PaC02 and administration of buffer solutions in 
the acute setting. Finally, 5 clinically meaningful and defined variables (IHD, age, arterial 
lactate, LVEF and MAP) were included in the multivariable logistic regression model.  
Regarding further differentiation of surgical procedures in addition to the euroSCORE II 
classification (Study II), many, if not most, surgical procedures entail anything from minor 
perioperative corrections without reinstitution of CPB such as additional suturing of graft 
anastomoses due to local bleeding further on to major re-interventions such as switching from 
failed minimally invasive valve repair to open heart valve replacement. Even if unplanned 
procedures may have a negative impact on the cardiovascular state of individual patients 
leading to need for VA-ECMO support such further subdivision into non-validated procedural 
subgroups besides the validated euroSCORE II classification model will not improve 
identification of procedure related outcome predictors. Instead, it might complicate 
interpretation of data and impair comparison between centers especially when the numbers of 
included patients are limited, besides having a negative impact on power, multicollinearity and 
external validity (generalizability) of our findings. It was therefore chosen to keep the 
subdivision of surgical procedural subgroups in accordance to the euroSCORE II model in this 
thesis. 
 
A further example of problematic collinearity addressed in the thesis concerns left and right 
ventricular deterioration. The vast majority of patients regardless of subgroup belonging, in 
addition to left ventricular deterioration, also had a significant right ventricular dysfunction. 
However, to determine if the right ventricular deterioration was of a primary, combined or 
secondary origin to left ventricular deterioration is challenging. Furthermore, in comparison 
to the relatively more precise echocardiographic quantification of left ventricular function, 
right ventricular deterioration was imprecisely characterized as being “significant” and thereby 
difficult to interpret. In addition, there was an extremely high correlation between “right 
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ventricular failure” and the LVEF in the multicollinearity analysis. Thus, we avoided 
introducing a right ventricular failure variable due to the above-mentioned reasons. 
5.4.3 Confounders 
With the aim to provide a model to predict outcome after VA-ECMO, potential confounders 
should be should be addressed.  For example, in Study II it may be questioned when LVEF 
and MAP were registered, before surgery or just before VA-ECMO, in order to analyze these 
variables as pre-VA-ECMO variables, as it is well known that when the heart is on CPB LVEF 
is difficult to assess. The LVEF was recorded just before initiation (cannulation) of VA-ECMO 
and not before surgery (Study II). LVEF can be difficult to assess during CPB at full CPB 
flow rates. However, in patients who cannot be weaned from CPB, VA-ECMO will only be 
initiated after weaning attempts from CPB have failed. Intraoperative transesophageal 
echocardiography (TEE) is the routine method and main diagnostic tool to perioperatively 
evaluate the biventricular function (LVEF, valves etc.) before separating the patient from CPB. 
LVEF is assessed at the lowest possible CPB flow (weaning) rate thereby enhancing the 
accuracy in LVEF evaluation compared with if the assessment would be attempted during full 
CPB flow (which underestimates LVEF as indicated by the remark given). This method is not 
different from the well-established routine method in predicting the probability of successful 
weaning by assessing LVEF during lowest possible VA-ECMO flow rate when weaning and 
separation is attempted from VA-ECMO support to a mechanically unsupported heart. 
Replacing pre-VA-ECMO LVEF for preoperative (pre-CPB) LVEF would in most cases also 
overestimate the “factual” pre-VA-ECMO LVEF, the latter being the LVEF which the 
decision mainly is made to initiate VA-ECMO upon. It would also be challenging to discuss 
why the proportion of patients with normal and near normal pre-CPB LVEF were not able to 
be separated from CPB, when the decision was made to initiate VA-ECMO in the same 
patients de facto having a lower postoperative pre-VA-ECMO LVEF i.e. patients would be 
classified to have postcardiotomy cardiogenic shock but with (falsely) preserved or near 
normal LVEF. Moreover, using pre-VA-ECMO LVEF is a more consistent approach when 
comparing post CPB/pre-VA-ECMO characteristics of patients regardless if they were 
transitioned from CPB directly to VA-ECMO or later during the first postoperative hours or 
days. To compare pre-CPB LVEF in the patients cannulated in the OR with the pre-VA-
ECMO LVEF in the patients cannulated later during the postoperative course would further 
complicate the assessment of pre-VA-ECMO LVEF as an outcome predictor as pre/post CPB 
LVEF is not the same variable in time. In summary, pre-CPB LVEF should not be used as a 
surrogate to pre-VA-ECMO LVEF as in the same way pre-VA-ECMO LVEF is not 
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considered when weaning from VA-ECMO is initiated if the aim is to assess the present LVEF 
influence on weaning success and outcome.  
The MAP was in the same way measured just before initiation (cannulation) of VA-ECMO 
not before CPB as pre-CPB MAP does not reflect the pre-VA-ECMO MAP after several hours 
of surgery, aortic cross clamp, cardioplegia, or in the patients who were transferred to the ICU 
before VA-ECMO support was initiated. 
It may be questioned why ECG as part of a cardiac evaluation just before VA-ECMO initiation 
was not included in the analysis in patients with refractory postcardiotomy cardiogenic shock.  
Systemic hypoperfusion caused by impaired myocardial contractility, is primarily verified by 
echocardiography (TTE/TEE) and hemodynamic monitoring, which are two of the clinical 
cornerstones included in the decision to initiate VA-ECMO support rather than ECG changes 
(Study II). In a minority of cases arrhythmias or electrocardiographic (ECG) ST-T changes 
can occur after cardioversion on CPB or during weaning from CPB, which depending on 
etiology in the majority of cases will respond either to or with a combination of pharmacology, 
cardioversion, pacemaker support, or in selected cases need for further reperfusion, valvular 
re-intervention or re-grafting of coronaries before final weaning from CPB or switch to VA-
ECMO support is undertaken. The vast majority of these intraoperatively registered ECG 
changes of critical etiology will thereby have resolved before separation from CPB or switch 
to VA-ECMO. Post-CPB or pre-VA-ECMO ECG has therefore not routinely been 
documented to allow for inclusion or evaluation in this retrospective study.  
 
5.5 CLINICAL IMPLICATIONS 
This thesis identified in total four independent pre-implant predictors for 90-day mortality in 
patients with refractory cardiogenic shock or cardiac arrest prior to VA-ECMO initiation. The 
identified independent predictors for 90-day mortality after VA-ECMO initiation related to the 
different study populations (Study I-IV) are presented in Table 16. These predictors are easily 
obtainable for pre-VA-ECMO risk prediction and may help to use VA-ECMO more efficiently 
for refractory cardiogenic shock in the different patient cohorts studied.  
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TABLE 16. Patient populations and identified independent pre-implant predictors of 90-day mortality after 
VA-ECMO initiation related to the studies included in the thesis 
Study Patient population Predictors of 90-day mortality 
I Unselected, refractory cardiogenic shock • Arterial lactate  
• No. of inotropes and vasopressors 
• Ischemic heart disease 
II Refractory postcardiotomy cardiogenic shock • Arterial lactate  
• Ischemic heart disease 
III Unselected non-surgical, refractory cardiogenic shock • Arterial lactate  
• No. of inotropes and vasopressors 
IV Cardiac arrest and CPR duration ≥1 minute before VA-
ECMO  
  
• Initial non-shockable rhythm 
• Ischemic heart disease  
• Arterial lactate 
CPR, cardiopulmonary resuscitation; VA-ECMO, venoarterial extracorporeal membrane oxygenation 
 
It should be noted that arterial lactate was a predictor of 90-day mortality in all studies (Study 
I-IV).  
In unselected patients with refractory cardiogenic shock (Study I), the arterial lactate level, 
the number of inotropes and vasopressors, and the presence of IHD were independent pre-VA-
ECMO predictors of 90-day mortality after VA-ECMO initiation.  
In Study II on patients with refractory postcardiotomy cardiogenic shock, arterial lactate level 
and IHD were independent pre-VA-ECMO predictors of 90-day mortality. Furthermore, 
Study II suggest that VA-ECMO should be considered before profound hyperlactatemia 
occurs, especially in patients with IHD. Importantly, our analysis further demonstrated that 
neither any of the four euroSCORE II cardiac surgical subgroups, cardioplegic route, aortic 
cross clamp and CPB time nor age or gender independently predicted 90-day mortality.  
In patients with unselected non-surgical refractory cardiogenic shock (Study III) arterial 
lactate level and number of inotropes and vasopressors were found to be independent 
preimplant predictors of 90-day mortality after VA-ECMO initiation. These findings imply 
that when VA-ECMO is considered it should be implanted before profound hyperlactatemia 
occurs and the number of inotropic and vasopressor agents has increased. Furthermore, this 
also implies not to prioritize specific etiologies of cardiogenic shock when deciding which 
patients that may benefit from VA-ECMO, decisions that often have to be made swiftly within 
the limited time available to assess complete information of the patient’s background.  
Study IV on unselected patients with cardiac arrest of verified or presumed cardiac etiology 
and with low-flow duration down to 1 minute prior to VA-ECMO initiation identified non-
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shockable rhythm, IHD, and arterial lactate as independent pre-implant predictors for 90-day 
mortality after VA-ECMO initiation, whereas age, low-flow duration and ROSC were not 
significant. These findings may facilitate rapid decision making in the extreme setting of 
cardiac arrest, irrespectively if patients are cannulated during CPR (ECPR) or due to 
refractory postarrest cardiogenic shock after ROSC. Furthermore, these findings imply that 
primarily initial cardiac arrest rhythm followed by metabolic assessment, i.e. arterial lactate 
level and/or presence of IHD are more important than strict age or time limits when VA-
ECMO is contemplated during CPR or in refractory postarrest cardiogenic shock. 
 
5.6 LIMITATIONS 
Some important limitations of the studies included in this thesis need to be mentioned. Study 
I-IV were based on retrospective observational data from a heterogeneous patient cohort with 
refractory cardiogenic shock and/or cardiac arrest followed by VA-ECMO and neither 
included matched control cohorts nor allowed for randomization. Nevertheless, the 
heterogeneity of patients with refractory cardiogenic shock and/or cardiac arrest reflects the 
clinical reality in tertiary centers offering VA-ECMO and therefore provides generalizability 
(external validity) of the findings. Furthermore, as data are observational, they are prone to 
selection bias and the limited sample sizes are too small to draw definitive recommendations.  
The limited sample sizes in this thesis cannot rule out the risk of Type II errors, exemplified 
by the variable age. In Study I-IV age did not reach significance in contrast to several studies 
within the field.2, 8, 32, 34, 40, 44-47, 49, 55, 111 However, this likely suggest that in previous less 
adjusted analyses age was important, whereas in our analysis, age was neutralized by the many 
other covariates in our study models. For example, age was associated with mortality in 
previous circulatory arrest studies related to VA-ECMO.104, 105, 113 However, in studies that 
included lactate age did not reach statistical significance.82, 83, 85, 86 
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6 CONCLUSIONS 
The specific conclusions were: 
• In unselected patients with refractory cardiogenic shock, the arterial lactate level, the 
number of inotropes and vasopressors, and the presence of IHD were identified as 
independent pre-implant predictors of 90-day mortality after VA-ECMO initiation. 
 
• In patients with refractory postcardiotomy cardiogenic shock, arterial lactate level and 
presence of IHD were identified as independent pre-implant predictors of 90-day 
mortality after VA-ECMO initiation. 
 
• In an unselected non-surgical population with refractory cardiogenic shock arterial 
lactate level and number of inotropes and vasopressors were identified as independent 
pre-implant predictors of 90-day mortality after VA-ECMO initiation. 
 
• In patients with cardiac arrest and CPR ≥1 minute before VA-ECMO initiation, non-
shockable rhythm, IHD, and arterial lactate were identified as independent pre-implant 
predictors of 90-day mortality after VA-ECMO initiation, whereas low-flow duration, 
ROSC and age were not significant. 
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